[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 609
1. Mamada Y, Yoshida H, Taniai N, Bandou K, Shimizu T, Kakinuma D, Mizuguchi Y, Ishikawa Y, Akimaru K, Tajiri T: Peritoneovenous shunts for palliation of malignant ascites. J Nippon Med Sch; 2007 Oct;74(5):355-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peritoneovenous shunts for palliation of malignant ascites.
  • BACKGROUND: Malignant ascites may produce a cluster of symptoms that include abdominal distention, early satiety, respiratory embarrassment, impaired mobility, and lethargy, and relief of these symptoms is often difficult to achieve.
  • We report on the placement of peritoneovenous shunts (PVSs) in a group of patients with malignant ascites, with particular reference to the effectiveness and complications of the procedure.
  • PATIENTS AND METHOD: PVSs were inserted in 9 patients with malignant ascites after obtaining their informed consent.
  • Median survival time after PVS placement was 21 days (range, 10 approximately 90 days), and the shunt was functioning at the time of death with good control of ascites in all patients.
  • CONCLUSIONS: Malignant ascites produces troublesome symptoms for patients, who may live for some time.
  • Placement of a PVS is a well-tolerated, relatively minor surgical procedure that can provide excellent control of ascites in most patients selected.
  • [MeSH-major] Ascites / surgery. Peritoneovenous Shunt

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17965529.001).
  • [ISSN] 1345-4676
  • [Journal-full-title] Journal of Nippon Medical School = Nippon Ika Daigaku zasshi
  • [ISO-abbreviation] J Nippon Med Sch
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


2. Heiss MM, Ströhlein MA, Jäger M, Kimmig R, Burges A, Schoberth A, Jauch KW, Schildberg FW, Lindhofer H: Immunotherapy of malignant ascites with trifunctional antibodies. Int J Cancer; 2005 Nov 10;117(3):435-43
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunotherapy of malignant ascites with trifunctional antibodies.
  • This concept was investigated in vivo in patients with malignant ascites in a clinical situation that allowed monitoring of tumor cell elimination and correlation with clinical effects.
  • In a prospective study, 8 patients with malignant ascites due to peritoneal carcinomatosis were treated with intraperitoneal application of trAb, which bound either the EpCAM- or Her2/neu-antigen on tumor cells.
  • Tumor cell monitoring showed a complete elimination of tumor cells in ascites already at total doses as low as 40-140 microg.
  • Clinical response with disappearance of ascites accumulation was seen in all patients, which was correlated with elimination of tumor cells (p = 0.0014).
  • Intraperitoneal immunotherapy with trAb showed convincing efficacy in patients with malignant ascites.
  • This treatment offers new therapeutic options for patients with peritoneal carcinomatosis.
  • [MeSH-major] Ascites / immunology. Immunotherapy. Peritoneal Neoplasms / pathology

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 15906359.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines; 0 / DNA Primers; 0 / Tumor Necrosis Factor-alpha
  •  go-up   go-down


3. Gupta R, Mathur SR, Iyer VK, Kumar A S, Seth A: Cytomorphologic consideration in malignant ascites with renal cell carcinoma: A report of two cases. Cytojournal; 2010;7:4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytomorphologic consideration in malignant ascites with renal cell carcinoma: A report of two cases.
  • Effusions, especially peritoneal, are seen in less than 2% of patients with renal cell carcinoma (RCC).
  • An accurate recognition of malignant effusion and differentiation from reactive mesothelial cells is imperative.
  • A 55-year-old male presented with gradually progressive ascites.
  • Considering the histomorphology of the primary renal tumor in both cases, a cytologic diagnosis of malignant peritoneal effusion, morphologically compatible with RCC was rendered.
  • A close inspection of the cytologic features and comparison with the histopathology of the primary tumor helps in making an accurate diagnosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chest. 1979 May;75(5):647-8 [436505.001]
  • [Cites] Acta Cytol. 1985 Sep-Oct;29(5):753-67 [2996273.001]
  • [Cites] Acta Cytol. 1987 Mar-Apr;31(2):85-97 [3469856.001]
  • [Cites] Arch Pathol Lab Med. 2006 Jun;130(6):823-7 [16740034.001]
  • [Cites] Diagn Cytopathol. 1995 Nov;13(4):304-9 [8599913.001]
  • [Cites] Cancer. 1998 Jun 25;84(3):148-52 [9678728.001]
  • [Cites] Histopathology. 2004 Nov;45(5):452-9 [15500648.001]
  • [Cites] Indian J Chest Dis Allied Sci. 1987 Jan-Mar;29(1):29-35 [3666836.001]
  • (PMID = 20436788.001).
  • [ISSN] 1742-6413
  • [Journal-full-title] CytoJournal
  • [ISO-abbreviation] Cytojournal
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2861821
  • [Keywords] NOTNLM ; Peritoneal effusion / cytology / mesothelial cells / renal cell carcinoma
  •  go-up   go-down


Advertisement
4. Saiz-Mendiguren R, Gómez-Ayechu M, Noguera JJ, García-Lallana A, Marginet C, Cano D, Benito A: [Permanent tunneled drainage for malignant ascites: initial experience with the PleurX® catheter]. Radiologia; 2010 Nov-Dec;52(6):541-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Permanent tunneled drainage for malignant ascites: initial experience with the PleurX® catheter].
  • [Transliterated title] Drenaje permanente tunelizado de la ascitis maligna: experiencia inicial con el catéter PleurX®.
  • OBJECTIVE: The most common treatment in recurrent malignant ascites is generally temporary peritoneal drainage.
  • CONCLUSION: Although the low number of patients in our series precludes generalizations, tunneled peritoneal catheters seem to be a safe and effective minimally invasive treatment for malignant ascites in terminal oncologic patients.
  • This approach facilitates the draining of the ascites at home, obviating the need for repeated hospital visits and punctures and the risks involved therein.
  • [MeSH-major] Ascites / therapy. Catheters, Indwelling. Drainage / instrumentation. Drainage / methods
  • [MeSH-minor] Adult. Aged. Equipment Design. Female. Humans. Male. Middle Aged. Peritoneal Neoplasms / complications. Ultrasonography, Interventional

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 SERAM. Published by Elsevier Espana. All rights reserved.
  • (PMID = 20863540.001).
  • [ISSN] 0033-8338
  • [Journal-full-title] Radiología
  • [ISO-abbreviation] Radiologia
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


5. Sevinc A, Sari R, Fadillioglu E: The utility of lactate dehydrogenase isoenzyme pattern in the diagnostic evaluation of malignant and nonmalignant ascites. J Natl Med Assoc; 2005 Jan;97(1):79-84

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The utility of lactate dehydrogenase isoenzyme pattern in the diagnostic evaluation of malignant and nonmalignant ascites.
  • Serum LDH isoenzymes may be useful in differential diagnosis of ascites etiology since tissue damage releases isoenzymes contained therein, leading to a change in their pattern.
  • MATERIALS AND METHODS: We determined ascitic fluid LDH level and LDH isoenzyme activities in patients with malignant and nonmalignant ascites in a total of 76 patients (43 males and 33 females).
  • RESULTS: LDH level, LDH-4 activity and LDH-5 activity were found to be significantly higher, and LDH-1 activity was found to be lower in malignant ascites when compared with nonmalignant ascites.
  • LDH-1 activity was detected to be significantly higher in the sterile cirrhotic ascites when compared with spontaneous bacterial peritonitis, malignant ascites, tuberculous ascites and congestive heart failure-related ascites.
  • LDH-3 activity was detected to be higher in spontaneous bacterial peritonitis, malignant ascites and tuberculous ascites when compared with the sterile cirrhotic ascites.
  • In the diagnosis of malignant ascites, the sensitivity and specificity were 96% and 76% for LDH level, 90% and 70% for LDH-1 activity, 94% and 62% for LDH-4 activity, and 100% and 56% for LDH-5 activity, respectively.
  • CONCLUSION: Ascitic LDH and its isoenzyme pattern may be helpful for the differential diagnosis of the most common causes of ascites: cirrhosis, spontaneous bacterial peritonitis, congestive heart failure, tuberculosis and malignancy.
  • [MeSH-major] Ascites / etiology. L-Lactate Dehydrogenase / metabolism
  • [MeSH-minor] Ascitic Fluid / enzymology. Bacterial Infections / complications. Diagnosis, Differential. Female. Heart Failure / complications. Humans. Isoenzymes / analysis. Liver Cirrhosis / complications. Male. Middle Aged. Neoplasms / complications. Peritonitis / complications. Sensitivity and Specificity. Tuberculosis / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Intern Med. 1972 Oct;77(4):507-13 [4642731.001]
  • [Cites] Scand J Respir Dis. 1966;47(2):150-6 [5180829.001]
  • [Cites] Vutr Boles. 1984;23(6):55-60 [6531874.001]
  • [Cites] Zhonghua Jie He He Hu Xi Za Zhi. 1990 Apr;13(2):71, 125 [2397532.001]
  • [Cites] Ann Clin Lab Sci. 1990 Jul-Aug;20(4):268-73 [2403242.001]
  • [Cites] Clin Chem. 1991 Aug;37(8):1419-23 [1651182.001]
  • [Cites] Clin Chem. 1991 Nov;37(11):1909-12 [1934463.001]
  • [Cites] Perit Dial Int. 1994;14(3):231-5 [7948233.001]
  • [Cites] Am J Med. 1996 Jan;100(1):1-7 [8579074.001]
  • [Cites] Chest. 1997 Mar;111(3):648-51 [9118702.001]
  • [Cites] Eur J Clin Chem Clin Biochem. 1997 Jul;35(7):523-8 [9263728.001]
  • [Cites] Gynecol Oncol. 1997 Sep;66(3):399-404 [9299252.001]
  • [Cites] Respir Med. 1999 May;93(5):338-41 [10464900.001]
  • [Cites] Ann N Y Acad Sci. 1961 Nov 2;94:912-32 [14008497.001]
  • [Cites] Cancer. 1984 Aug 1;54(3):507-11 [6733680.001]
  • (PMID = 15719876.001).
  • [ISSN] 1943-4693
  • [Journal-full-title] Journal of the National Medical Association
  • [ISO-abbreviation] J Natl Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Isoenzymes; EC 1.1.1.27 / L-Lactate Dehydrogenase; EC 1.1.1.27 / lactate dehydrogenase 2; EC 1.1.1.27 / lactate dehydrogenase 3; EC 1.1.1.27 / lactate dehydrogenase 4; EC 1.1.1.27.- / lactate dehydrogenase 1
  • [Other-IDs] NLM/ PMC2568581
  •  go-up   go-down


6. Sebastian M: Review of catumaxomab in the treatment of malignant ascites. Cancer Manag Res; 2010;2:283-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Review of catumaxomab in the treatment of malignant ascites.
  • Malignant ascites is frequently found with various solid tumors, and no established treatment options exist, apart from symptomatic paracentesis.
  • Intraperitoneal treatment with catumaxomab resulted in a significant prolongation of puncture-free survival in patients with malignant ascites due to epithelial cancer.
  • Catumaxomab has been approved in Europe for the intraperitoneal treatment of malignant ascites in patients with EpCAM-positive epithelial tumors where standard therapy is not available or no longer feasible.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21188120.001).
  • [ISSN] 1179-1322
  • [Journal-full-title] Cancer management and research
  • [ISO-abbreviation] Cancer Manag Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC3004584
  • [Keywords] NOTNLM ; ascites / catumaxomab / epithelial cell adhesion molecule
  •  go-up   go-down


7. Takano M, Sugiyama T, Yaegashi N, Suzuki M, Tsuda H, Sagae S, Udagawa Y, Kuzuya K, Kigawa J, Takeuchi S, Tsuda H, Moriya T, Kikuchi Y: Progression-free survival and overall survival of patients with clear cell carcinoma of the ovary treated with paclitaxel-carboplatin or irinotecan-cisplatin: retrospective analysis. Int J Clin Oncol; 2007 Aug;12(4):256-60
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: One hundred and seventeen patients at International Federation of Gynecology and Obstetrics (FIGO) stages Ic (ascites/malignant washing) - IV were identified by scanning the medical records of ten Japanese hospitals.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17701003.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 7673326042 / irinotecan; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


8. Bodisch A, Muschitz C, Karthaus M: [Methods of symptom control in malignant ascites]. Wien Med Wochenschr; 2008;158(23-24):687-94
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Methods of symptom control in malignant ascites].
  • [Transliterated title] Maligner Ascites--Möglichkeiten der Symptomkontrolle.
  • Ascites remains a challenge in many patients with advanced cancers in palliative care.
  • On the basis of a case report, different attempts to control malignant ascites are discussed.
  • The report of a young woman with relapsing ovarian cancer and recurrent ascites is presented including the management of symptomatic malignant ascites.
  • [MeSH-major] Ascites / therapy. Neoplasm Recurrence, Local / therapy. Ovarian Neoplasms / therapy. Palliative Care / methods. Peritoneal Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19165448.001).
  • [ISSN] 0043-5341
  • [Journal-full-title] Wiener medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Wien Med Wochenschr
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Diuretics
  •  go-up   go-down


9. Kaushik N, Khalid A, Brody D, McGrath K: EUS-guided paracentesis for the diagnosis of malignant ascites. Gastrointest Endosc; 2006 Dec;64(6):908-13
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EUS-guided paracentesis for the diagnosis of malignant ascites.
  • BACKGROUND: EUS and EUS-guided fine-needle aspiration (EUS-FNA) have well-defined roles in the diagnosis and staging of GI and pancreaticobiliary malignancy.
  • Malignant ascites usually represents peritoneal carcinomatosis, increases disease stage, and portends a poor prognosis.
  • There are limited data regarding the yield of EUS-guided paracentesis (EUS-P) for the diagnosis of malignant ascites.
  • OBJECTIVE: To determine the usefulness of EUS-P for the diagnosis of malignant ascites.
  • PATIENTS: Those presenting for EUS examination for suspected or proven malignancy over a 16-month period were evaluated prospectively for the presence of ascites.
  • INTERVENTIONS: EUS-P was performed via a transgastric or transduodenal approach if ascites was detected.
  • MAIN OUTCOME MEASUREMENTS: Sensitivity, specificity, positive predictive value, and negative predictive value of EUS-P for diagnosing malignant ascites.
  • Twenty-five patients with ascites who met inclusion criteria comprised the study cohort.
  • The mean volume of ascites aspirated was 6.8 mL (range, 1-20 mL).
  • Sixty-four percent (16 of 25) of EUS-P samples revealed malignant cytology.
  • The sensitivity, specificity, positive predictive value, and negative predictive value of EUS-P for diagnosing malignant ascites was 94%, 100%, 100%, and 89%, respectively.
  • LIMITATIONS: The study did not address cost savings in patient care based on the diagnosis of malignant ascites.
  • CONCLUSIONS: EUS-P is highly sensitive and specific for diagnosing malignant ascites.
  • The finding of malignant ascites significantly alters patient management, so an active search for ascites and use of EUS-P should be incorporated into the diagnosis and staging of upper GI and pancreaticobiliary malignancy.
  • [MeSH-major] Ascites / ultrasonography. Endosonography. Paracentesis / methods. Peritoneal Neoplasms / diagnosis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17140897.001).
  • [ISSN] 0016-5107
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. DeWitt J, Yu M, Al-Haddad MA, Sherman S, McHenry L, Leblanc JK: Survival in patients with pancreatic cancer after the diagnosis of malignant ascites or liver metastases by EUS-FNA. Gastrointest Endosc; 2010 Feb;71(2):260-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival in patients with pancreatic cancer after the diagnosis of malignant ascites or liver metastases by EUS-FNA.
  • BACKGROUND: The expected survival after the EUS-FNA diagnosis of malignant ascites or liver metastases from pancreatic cancer is not known.
  • PATIENTS: Consecutive subjects with newly diagnosed pancreatic cancer from June 1998 and March 2008 in whom EUS-FNA of the liver or ascitic fluid confirmed hepatic metastases or malignant ascites.
  • INTERVENTIONS: Calculation of survival after diagnosis by using the Social Security Death Index.
  • MAIN OUTCOME MEASUREMENTS: Survival after EUS-FNA diagnosis of stage IV pancreatic cancer.
  • RESULTS: EUS-FNA identified liver metastases and malignant ascites from primary pancreatic cancer in 75 and 13 patients, respectively, and all 88 died during follow-up.
  • The 1-year survival rates for those with liver metastases (4.0% [95% CI, 1.3%-12.1%]) and for those with malignant ascites (0% [95% CI, 0-24.7%]) were similar (P = 1.0).
  • The median survival for patients with liver metastases of 83 days (range 2-754 days) was similar to that for those with malignant ascites (64 days; range 2-153 days) (P = .13).
  • CONCLUSIONS: In patients with pancreatic cancer, identification of malignant ascites or liver metastases by EUS-FNA is associated with a very poor prognosis.
  • [MeSH-major] Ascites / pathology. Endosonography / methods. Liver Neoplasms / mortality. Liver Neoplasms / secondary. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / mortality
  • [MeSH-minor] Aged. Aged, 80 and over. Biopsy, Fine-Needle / methods. Cause of Death. Cohort Studies. Education, Medical, Continuing. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. Peritoneal Neoplasms / mortality. Peritoneal Neoplasms / pathology. Peritoneal Neoplasms / secondary. Probability. Prognosis. Retrospective Studies. Risk Assessment. Statistics, Nonparametric. Survival Analysis. Time Factors


11. Rana SV, Babu SG, Kocchar R: Usefulness of ascitic fluid cholesterol as a marker for malignant ascites. Med Sci Monit; 2005 Mar;11(3):CR136-42
Hazardous Substances Data Bank. CHOLESTEROL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Usefulness of ascitic fluid cholesterol as a marker for malignant ascites.
  • BACKGROUND: The differential diagnosis of ascites is a common clinical problem.
  • However, the capability to distinguish malignant from non-malignant causes of ascites using available biochemical techniques would obviate many expensive and time-consuming diagnostic studies on patients presenting with ascites of unknown etiology.
  • Therefore, this study was planned to evaluate the diagnostic efficacy of ascitic fluid cholesterol in comparison to the efficiency of ascitic/serum total protein, pH, glucose, total leukocyte count, and the serum/ascitic albumin gradient in differentiating "malignant" from non-malignant ascites.
  • MATERIALS/METHODS: A total of 50 patients (25 with malignant ascites and 25 with non-malignant) were evaluated for total ascitic protein, ascites/serum (A/S) total protein ratio, serum ascites albumin gradient (SAAG), ascitic pH, serum & ascitic cholesterol with glucose.
  • RESULTS: The mean ascitic cholesterol level was significantly higher in malignant ascites than in non-malignant ascites, with a cut off level of 70 mg/dl for ascitic fluid cholesterol; 22/25 (88%) patients with malignant ascites could be separated from the 25 patients with non-malignant ascites.
  • CONCLUSIONS: Total Ascitic protein (70%), Ascitic serum protein ratio (74%), ascitic leukocyte count (54%), and malignant cytology (82%) yielded much lower diagnostic efficiency than ascitic fluid cholesterol (94%) or SAAG (86%) in the diagnosis of malignant ascites.
  • [MeSH-major] Ascites / etiology. Ascitic Fluid / chemistry. Biomarkers / analysis. Cholesterol / analysis. Peritoneal Neoplasms / complications
  • [MeSH-minor] Adolescent. Adult. Aged. Diagnosis, Differential. Evaluation Studies as Topic. Female. Humans. India. Laparotomy. Male. Middle Aged. Predictive Value of Tests

  • MedlinePlus Health Information. consumer health - Cholesterol.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15735567.001).
  • [ISSN] 1234-1010
  • [Journal-full-title] Medical science monitor : international medical journal of experimental and clinical research
  • [ISO-abbreviation] Med. Sci. Monit.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers; 97C5T2UQ7J / Cholesterol
  •  go-up   go-down


12. Rosenberg SM: Palliation of malignant ascites. Gastroenterol Clin North Am; 2006 Mar;35(1):189-99, xi
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Palliation of malignant ascites.
  • The management of recurrent, symptomatic malignant ascites can be problematic for physicians and patients.
  • Patient disease progression often leads to rapid reaccumulation of ascites, which requires frequent return visits to the hospital for symptom management.
  • Other techniques have been developed to achieve palliation of symptoms, including tunneled external drainage catheters, peritoneal ports, and peritoneovenous
  • [MeSH-major] Ascites / therapy. Palliative Care

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Surg Educ. 2007 Jan-Feb;64(1):4-9 [17320802.001]
  • (PMID = 16530120.001).
  • [ISSN] 0889-8553
  • [Journal-full-title] Gastroenterology clinics of North America
  • [ISO-abbreviation] Gastroenterol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 49
  •  go-up   go-down


13. Trinh X, van Dam P, Tjalma W, Wojtasik A, Lybaert W, Rasschaert M, Rutten A, Prové A, Vermeulen P, Dirix L: An open-label phase II trial to assess to efficacy of sunitinib as an antieffusion agent in patients with malignant peritoneal and/or pleural effusions. J Clin Oncol; 2009 May 20;27(15_suppl):e14647

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An open-label phase II trial to assess to efficacy of sunitinib as an antieffusion agent in patients with malignant peritoneal and/or pleural effusions.
  • : e14647 Background: Pleural and peritoneal effusions are common in advanced malignant disease and relative resistant to traditional treatments.
  • VEGF-A is considered to be a crucial factor in the biology of accumulation of malignant effusions (ME).
  • EFFICACY: Three (3/6) patients showed regression of effusion fluid by consecutive CT-scans.
  • Of which, one had sustained reduction in volume fluid accumulation, while the other one had initial stabilisation after one cycle but eventually had increasing volume of ascites.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964234.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Lu L, Schafer P, Bartlett JB: Inhibition by lenalidomide of growth factor and hypoxia-induced signaling in endothelial and epithelial tumor cells, and effects within the tumor cell microenvironment. J Clin Oncol; 2009 May 20;27(15_suppl):e14620

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lenalidomide studies in CLL and MM suggest that it may also attenuate pro-survival signals generated by interaction of stroma with the malignant cell itself.
  • Lysophosphatidic acid (LPA) is a key pro-survival factor present at high levels within the ascites of ovarian cancer patients which confers increased tumor invasiveness and reduced survival.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964203.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Parsons S, Hennig M, Linke R, Klein A, Lahr A, Lindhofer H, Heiss M: Clinical benefit of catumaxomab in malignant ascites in patient subpopulations in a pivotal phase II/III trial. J Clin Oncol; 2009 May 20;27(15_suppl):e14000

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical benefit of catumaxomab in malignant ascites in patient subpopulations in a pivotal phase II/III trial.
  • : e14000 Background: Parsons et al. (ASCO 2008) reported the results of a pivotal phase II/III trial in patients with malignant ascites due to epithelial cancer.
  • Malignant ascites is a typical late-stage manifestation of cancer associated with a poor prognosis and survival.
  • CONCLUSION: Catumaxomab demonstrated a significant clinical benefit in patients with malignant ascites independent of the primary tumor or other prognostic factors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961494.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Xie L, Chen X, Qian X, Wei J, Ding Y, Zhang C, Liu B: Cell-free miR-10b and miR-21 as diagnostic biomarkers for malignant effusions. J Clin Oncol; 2009 May 20;27(15_suppl):11035

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell-free miR-10b and miR-21 as diagnostic biomarkers for malignant effusions.
  • : 11035 Background: Numerous studies have proved the roles of tissue microRNAs (miRNAs) as biomarkers in cancer diagnosis.
  • Cell-free miRNAs from plasma or serum have been shown to be good biomarkers in the diagnosis of cancers.
  • Here we tried to explore the potential application of cell-free miRNAs as diagnostic biomarkers to discriminate malignant effusions from benign.
  • METHODS: To obtain a molecular signature for malignant effusions, a stem-loop real-time PCR was adopted to measure the expression of 23 tumor-related miRNAs.
  • After a pre-screening for discarding low amount miRNAs in 10 samples (5 benign/5 malignant) and a proper internal control was identified, the expression levels of 7 miRNAs were further compared among 74 malignant effusion samples (35 gastric cancer-related ascites and 39 lung cancer-related plural effusions) and 30 benign effusions. miRNAs specifically associated with malignant effusions were derived from a training group (20 malignant/10 benign) and tested in a validation group (54 malignant/20 benign).
  • All samples were confirmed by both pathological and clinical diagnosis.
  • The expression of miR-10b was significantly different between benign and malignant effusions (P< 0.001).
  • Furthermore, it was showed that miR-10b can distinguish malignant plural effusions with high accuracy (areas under the curve (AUC) of receiver operating characteristic (ROC) curve 0.98, 95% CI, 0.90 to 1.0, P< 0.001), and miR-21 can be used to discriminate malignant ascites (AUC of ROC curve 0.71, 95% CI, 0.56 to 0.83, P= 0.018).
  • CONCLUSIONS: In the present study, we demonstrated that cell-free miRNA can serve as a novel diagnostic biomarker in distinguishing malignant from benign effusions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964012.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Bokemeyer C, Heiss M, Gamperl H, Linke R, Schulze E, Friccius-Quecke H, Lindhofer H, Parsons S: Safety of catumaxomab: Cytokine-release-related symptoms as a possible predictive factor for efficacy in a pivotal phase II/III trial in malignant ascites. J Clin Oncol; 2009 May 20;27(15_suppl):3036

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety of catumaxomab: Cytokine-release-related symptoms as a possible predictive factor for efficacy in a pivotal phase II/III trial in malignant ascites.
  • The clinical relevance of this mode of action was demonstrated by Parsons et al. (ASCO 2008) in a pivotal phase II/III trial.
  • Catumaxomab treatment resulted in a clinically relevant prolongation of puncture-free survival (defined as time to next puncture or time to death, which ever occurred first) in patients with malignant ascites.
  • CONCLUSIONS: CRRSs are a common occurrence with catumaxomab, due to its mode of action, during the treatment of patients with malignant ascites.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962076.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Ishigami H, Kitayama J, Kaisaki S, Hidemura A, Kato M, Otani K, Kamei T, Soma D, Miyato H, Yamashita H, Nagawa H: Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis. J Clin Oncol; 2009 May 20;27(15_suppl):4542

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis.
  • : 4542 Background: A phase II study to evaluate the efficacy and tolerability of weekly intravenous and intraperitoneal paclitaxel combined with S-1 was performed in gastric cancer patients with peritoneal metastasis.
  • METHODS: Gastric cancer patients with peritoneal dissemination and/or cancer cells on peritoneal cytology were enrolled.
  • Secondary endpoints were the response rate, efficacy against malignant ascites and safety.
  • RESULTS: Forty patients were enrolled, including 21 with primary tumors with peritoneal dissemination confirmed by staging laparoscopy, 13 with peritoneal recurrence, and 6 with positive peritoneal cytology only.
  • Malignant ascites disappeared or decreased in 13 of 21 (62%) patients.
  • Catheter obstruction observed in one patient was the only complication related to the peritoneal access device or intraperitoneal infusion.
  • CONCLUSIONS: Combination chemotherapy of intravenous and intraperitoneal paclitaxel with S-1 is well tolerated and active in gastric cancer patients with peritoneal metastasis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963015.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Jäger M, Schoberth A, Theissen B, Hess J, Friccius-Quecke H, Lindhofer H: Decrease of VEGF within malignant ascites during catumaxomab treatment: Results from a pivotal phase II/III study. J Clin Oncol; 2009 May 20;27(15_suppl):3029

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decrease of VEGF within malignant ascites during catumaxomab treatment: Results from a pivotal phase II/III study.
  • : 3029 Background: Treatment with the trifunctional anti-EpCAM x anti-CD3 antibody catumaxomab efficiently eliminates tumor cells from the peritoneal cavity (Jäger et al., ASCO 2007) and led to clinically relevant prolongation of puncture-free survival (PuFS) in patients with malignant ascites (MA) in a pivotal phase II/III trial (Parsons et al., ASCO 2008).
  • As vascular endothelial growth factor (VEGF) levels are markedly elevated in MA in comparison to cirrhotic ascites the question was addressed whether catumaxomab treatment impacts the expression or accumulation of VEGF within MA.
  • CONCLUSIONS: Catumaxomab therapy significantly reduced VEGF protein levels correlating with tumor cell elimination in MA, which in turn led to the prevention of fluid accumulation in the peritoneal cavity and finally to prolonged PuFS of patients suffering from MA.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962064.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Lindhofer H, Schoberth A, Pelster D, Hess J, Herold J, Jäger M: Elimination of cancer stem cells (CD133+/EpCAM+) from malignant ascites by the trifunctional antibody catumaxomab: Results from a pivotal phase II/III study. J Clin Oncol; 2009 May 20;27(15_suppl):3014

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elimination of cancer stem cells (CD133+/EpCAM+) from malignant ascites by the trifunctional antibody catumaxomab: Results from a pivotal phase II/III study.
  • The trifunctional anti-EpCAM x anti-CD3 antibody catumaxomab efficiently eliminates tumor cells from the peritoneal fluid of malignant ascites (MA) patients as demonstrated in a pivotal phase II/III trial (Parsons et al., ASCO 2008).
  • Here we report on the presence of CD133+/EpCAM+ putative CSCs in MA and, more importantly, on the elimination of this cell population from the peritoneal fluid of MA patients by means of catumaxomab therapy.
  • METHODS: 18 CTX-refractory patients with MA caused by a variety of primary carcinoma diseases (i.e., ovarian, pancreas, and gastric cancer) were analyzed for the presence CD133+/EpCAM+ cells in peritoneal fluids by means of CD133+/EpCAM+ double staining on cytospin preparations.
  • RESULTS: Before therapeutic intervention, CD133+/EpCAM+ cells were detected in the peritoneal fluids of 14 from 18 patients suffering from MA.
  • After 4 i.p. catumaxomab infusions (10μg day 0, 20μg day 3, 50μg day 7 and 150μg day 10) the CD133+/EpCAM+ cells were completely eliminated from the peritoneal fluids of all 14 MA patients.
  • CONCLUSIONS: In a preliminary monitoring study, putative CSCs (CD133+/EpCAM+) were present in peritoneal fluids of 78 % of analyzed MA patients with different underlying primary tumor entities.
  • Catumaxomab efficiently destroyed CD133+/EpCAM+ cells within peritoneal fluids of MA patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962058.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Kitayama J, Ishigami H, Kaisaki S, Hidemura A, Kato M, Nagawa H: Combined chemotherapy of intravenous and intraperitoneal paclitaxel with S-1 for malignant ascites due to advanced gastric cancer with peritoneal dissemination. J Clin Oncol; 2009 May 20;27(15_suppl):e15524

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined chemotherapy of intravenous and intraperitoneal paclitaxel with S-1 for malignant ascites due to advanced gastric cancer with peritoneal dissemination.
  • : e15524 Background: Malignant ascites caused by peritoneal metastasis the most life-threatening mode of metastasis and recurrence and seriously impair the quality of life in patients with gastric cancer.
  • METHODS: Twenty one patients with malignant ascites due to the peritoneal dissemination of gastric cancer were enrolled.
  • The volume of malignant ascites was objectively measured with the calculation of the consecutive computed tomography (CT) images using NIH image J software.
  • Peritoneal cytology and mRNA of CEA in acitic fluid were also evaluated in 17 and 16 cases, respectively.
  • RESULTS: The volume of malignant ascites before the treatment was more than 500ml in 8 patients and less than 300ml in 13 patients.
  • Malignant cells in peritoneal cytology disappeared in 13 cases while CEA mRNA became negative only in 2 cases.
  • The one year overall survival was 71% in all patients and 85% in patients with reduced ascites.
  • CONCLUSIONS: Combined chemotherapy of intravenous and intraperitoneal paclitaxel with S-1 was a useful protocol for malignant ascites caused by peritoneal dissemination of gastric cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962255.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Antos F, Dytrych P, Vítek P, Ryska O, Marvan J, Serclovlá Z: [Malignant ascites--optional management using hyperthermic peroperative chemotherapy (HIPEC)]. Rozhl Chir; 2010 Apr;89(4):237-41

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant ascites--optional management using hyperthermic peroperative chemotherapy (HIPEC)].
  • [Transliterated title] Maligní ascites--moznost ovlivnĕní tvorby pomocí hypertermické peroperacní chemoterapie (HIPEC).
  • 146 procedures using hyperthermic intraoperative peritoneal chemotherapy (HIPEC) were performed in 121 patients in the FNB Surgical Clinic, during 2000-2008.
  • During these procedures, ascites was detected in 30 subjects (24.8%) and its volume was 250-11,000 ml.
  • Out of the total of 22 subjects in Subgroup A, ascites was not postoperatively recorded in 17 patients.
  • In 5 patients, ascites was gradually formed from month 6.3 onwards, however, it only reached subclinical levels.
  • In Subgroup B (8 patients), no ascites was detected in 3 subjects until their death (37.5%), further 5 subjects presented with ascites at the mean postoperative month 7.25.
  • There was a statistically significant difference between the two subgoups in the survival time parametres (p = 0.009), thereas, the difference in ascites relapse rates was statistically insignificant (p = 0.12).
  • CONCLUSIONS: HIPEC with/without debulking is an efficient method for controlling, managing or preventing the development of malignant ascites, it extends the mean survival time of the patients (especially when bulking is feasible) with low morbidity and lethality rates of the procedure.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Ascites / therapy. Hyperthermia, Induced. Intraoperative Care. Neoplasms / complications. Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20586160.001).
  • [ISSN] 0035-9351
  • [Journal-full-title] Rozhledy v chirurgii : měsíčník Československé chirurgické společnosti
  • [ISO-abbreviation] Rozhl Chir
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


23. Andorsky DJ, Yamada R, Steward K, De Vos S, Said J, Timmerman J: Expression of programmed death ligand 1 (PD-L1) by non-Hodgkin's lymphomas (NHL) and effect on tumor-associated T cells. J Clin Oncol; 2009 May 20;27(15_suppl):8526

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To further test tumor-T cell interactions, malignant ascites from a patient with ALK+ ALCL and peripheral blood mononuclear cells from a patient with leukemic mantle cell lymphoma, both containing PD-L1-expressing tumor cells and tumor-associated T cells, were stimulated with phytohemagglutinin (a polyclonal T cell activator) and incubated with anti-PD-L1 antibody.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960901.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Stange R, Jänsch A, Schrag S, Pflugbeil C, Schlodder D, Pandey-Hoffmann U, Uehleke B: [Favourable course of persisting malignant ascites]. Forsch Komplementmed; 2009 Feb;16(1):49-53
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Favourable course of persisting malignant ascites].
  • [Transliterated title] Gunstiger Verlauf eines persistierenden malignen Aszites.
  • Malignant ascites is a frequent complication in oncological diseases.
  • We report the case of a woman, aged 49 years at the time of primary diagnosis, who suffered from recurrent ascites resulting from liver metastasis of breast cancer.
  • [MeSH-major] Ascites. Breast Neoplasms / pathology. Liver Neoplasms / complications. Liver Neoplasms / secondary. Mistletoe / chemistry. Phytotherapy. Plant Extracts / therapeutic use

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19295230.001).
  • [ISSN] 1661-4127
  • [Journal-full-title] Forschende Komplementärmedizin (2006)
  • [ISO-abbreviation] Forsch Komplementmed
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Immunologic Factors; 0 / Plant Extracts; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


25. Chung M, Kozuch P: Treatment of malignant ascites. Curr Treat Options Oncol; 2008 Jun;9(2-3):215-33
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of malignant ascites.
  • OPINION STATEMENT: The management of malignant ascites is a significant challenge in gastrointestinal medical oncology.
  • Current treatment strategies include diuretic therapy, paracentesis, peritoneal drains, and venous shunts.
  • By summarizing published studies, this review is intended to add some clarity to currently available strategies for the management of malignant ascites associated with hepatobiliary cancers.
  • Notably, however, much of the available data for the management of malignant ascites comes from the gynecologic oncology experience, specifically from studies in ovarian cancer.
  • Therefore, successful approaches used in this malignancy may be lead candidates for development in hepatobiliary cancer-associated ascites and are reviewed in this paper.
  • [MeSH-major] Ascites / physiopathology. Ascites / therapy. Gastrointestinal Neoplasms / therapy. Peritoneal Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18777213.001).
  • [ISSN] 1534-6277
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; EC 3.4.24.- / Matrix Metalloproteinases
  • [Number-of-references] 80
  •  go-up   go-down


26. Yuan ZP, Chen LJ, Wei YQ, Fan LY, Tang MH, Yang GL: [Nanoliposomal quercetin inhibits formation of malignant ascites of hepatocellular carcinoma]. Ai Zheng; 2006 Aug;25(8):941-5
Hazardous Substances Data Bank. QUERCETIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Nanoliposomal quercetin inhibits formation of malignant ascites of hepatocellular carcinoma].
  • This study was to investigate the biodistribution of quercetin encapsulated by pegylated nanoliposomes and its therapeutic efficacy on the formation of carcinomatous ascites of hepatocellular carcinoma in mice.
  • The formation of malignant ascites, increase of body weight, survival time and peritoneal capillary permeability were assessed.
  • Apoptotic cells in ascites were detected by flow cytometry.
  • Nanoliposome quercetin inhibited the formation of malignant ascites of hepatocellular carcinoma model in a dose-dependent manner.
  • Moreover, 100 mg/kg nanoliposomal quercetin significantly enhanced the apoptosis of cancer cells in ascites, inhibited the increase of body weight, reduced peritoneal capillary permeability and prolonged the survival time of tumor-bearing mice compared with PBS control.
  • CONCLUSION: Nanoliposomal quercetin can effectively accumulate in tumor tissues and inhibit the formation of malignant ascites, thus it might be used as a potential antitumor drug which deserves future study.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / pharmacology. Apoptosis / drug effects. Ascites / prevention & control. Carcinoma, Hepatocellular / pathology. Liver Neoplasms / pathology. Quercetin / pharmacology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16965672.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Liposomes; 30IQX730WE / Polyethylene Glycols; 9IKM0I5T1E / Quercetin
  •  go-up   go-down


27. Hosoya Y, Kobayashi E, Takizawa T, Fujimura A, Yasuda Y, Nagai H, Kanazawa K: Effect of intraperitoneal neutrophils induced by OK432 on malignant ascites. Surg Today; 2005;35(1):60-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of intraperitoneal neutrophils induced by OK432 on malignant ascites.
  • PURPOSE: To evaluate the efficacy of a streptococcal preparation, OK432, on malignant ascites in mice.
  • [MeSH-major] Ascites / pathology. Neoplasm Transplantation / mortality. Neutrophils / physiology. Peritoneal Neoplasms / pathology. Picibanil / pharmacology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15622466.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Cytokines; 39325-01-4 / Picibanil
  •  go-up   go-down


28. Catumaxomab: malignant ascites: unjustified marketing authorisation. Prescrire Int; 2010 Oct;19(109):207-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Catumaxomab: malignant ascites: unjustified marketing authorisation.
  • The only treatment for malignant ascites in patients with refractory cancer is paracentesis, a procedure to relieve symptoms.
  • Catumaxomab, a monoclonal antibody, is now authorised in the European Union for intraperitoneal administration to patients with epithelial cancers that overexpress epithelial cellular adhesion molecule (EpCAM) and provoke ascites unresponsive to chemotherapy.
  • [MeSH-major] Antibodies, Bispecific / adverse effects. Ascites / drug therapy. Cell Adhesion Molecules / antagonists & inhibitors. Marketing / legislation & jurisprudence. Neoplasms, Glandular and Epithelial / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21180374.001).
  • [ISSN] 1167-7422
  • [Journal-full-title] Prescrire international
  • [ISO-abbreviation] Prescrire Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antibodies, Bispecific; 0 / Antigens, Neoplasm; 0 / Cell Adhesion Molecules; 0 / catumaxomab; 0 / tumor-associated antigen GA733
  •  go-up   go-down


29. Yonemori K, Okusaka T, Ueno H, Morizane C, Takesako Y, Ikeda M: FP therapy for controlling malignant ascites in advanced pancreatic cancer patients. Hepatogastroenterology; 2007 Dec;54(80):2383-6
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FP therapy for controlling malignant ascites in advanced pancreatic cancer patients.
  • BACKGROUND/AIMS: Malignant ascites is one of the poor prognostic factors for pancreatic cancer, and causes serious symptoms and treatment-related toxicity.
  • We conducted a retrospective analysis to evaluate the efficacy of 5-fluorouracil (5-FU) plus cisplatin (FP therapy) for controlling malignant ascites in patients with advanced pancreatic cancer.
  • METHODOLOGY: This analysis was based on 28 consecutive chemotherapy-naive advanced pancreatic cancer patients with cytologically proven malignant ascites who were treated with FP therapy from November 1991 to April 2003.
  • The objective improvement of ascites was seen in 35.7% of the patients (N = 10/28, 95% confidence interval, 18.0 to 53.4%), but there was no patient with complete disappearance of ascites.
  • In all pretreatment variables, the presence of distant metastasis other than peritoneal dissemination was an unfavorable predictive factor for the objective improvement of ascites (Fisher's exact test: P = 0.002).
  • CONCLUSIONS: FP therapy was modestly effective for controlling malignant ascites but insufficient in shrinking for measurable metastatic lesions.
  • Systemic chemotherapy for controlling malignant ascites might be worth while for palliative management in advanced pancreatic cancer patients, especially in patients without distant metastasis.
  • [MeSH-major] Adenocarcinoma / complications. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ascites / drug therapy. Cisplatin / administration & dosage. Fluorouracil / administration & dosage. Pancreatic Neoplasms / complications

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18265670.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 9007-41-4 / C-Reactive Protein; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


30. Brooks RA, Herzog TJ: Long-term semi-permanent catheter use for the palliation of malignant ascites. Gynecol Oncol; 2006 May;101(2):360-2
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term semi-permanent catheter use for the palliation of malignant ascites.
  • BACKGROUND: Malignant ascites is a common complication of advanced or recurrent ovarian cancer and multiple other neoplasms, causing significant patient morbidity as well as a large treatment obstacle for the physician.
  • While multiple methods of peritoneal drainage have been reported, including large volume therapeutic paracentesis, peritoneogastric, peritoneourinary, and peritoneovenous shunting procedures, peritoneal port-a-catheter placement and hemodialysis catheter drainage, all have their associated limitations and adverse effects.
  • CASE: We report off label semi-permanent catheter placement in a patient for treatment of malignant ascites that functioned effectively with drainage of 2 l daily for approximately 18 months, the longest reported use in the literature.
  • CONCLUSION: Long-term semi-permanent catheter use is a potentially valuable modality for the palliation of malignant ascites.
  • [MeSH-major] Ascites / therapy. Catheterization / instrumentation. Drainage / instrumentation. Ovarian Neoplasms / therapy. Palliative Care / methods

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16499957.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Saif MW, Siddiqui IA, Sohail MA: Management of ascites due to gastrointestinal malignancy. Ann Saudi Med; 2009 Sep-Oct;29(5):369-77

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of ascites due to gastrointestinal malignancy.
  • Ascites is the pathological accumulation of fluid within the abdominal cavity.
  • The most common cancers associated with ascites are adenocarcinomas of the ovary, breast, colon, stomach and pancreas.
  • There are many potential causes of ascites in cancer patients, including peritoneal carcinomatosis, malignant obstruction of draining lymphatics, portal vein thrombosis, elevated portal venous pressure from cirrhosis, congestive heart failure, constrictive pericarditis, nephrotic syndrome and peritoneal infections.
  • Median survival after diagnosis of malignant ascites is in the range of 1 to 4 months; survival is apt to be longer for ovarian and breast cancers if systemic anti-cancer treatments are available.
  • [MeSH-major] Adenocarcinoma / complications. Ascites / therapy. Neoplasms / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ital J Gastroenterol Hepatol. 1999 Oct;31(7):626-34 [10604107.001]
  • [Cites] Clin Cancer Res. 1996 Jul;2(7):1207-14 [9816289.001]
  • [Cites] Int J Oncol. 2000 Mar;16(3):445-54 [10675474.001]
  • [Cites] Palliat Med. 2000 Jan;14(1):62-4 [10717726.001]
  • [Cites] Arch Intern Med. 2001 Dec 10-24;161(22):2733-7 [11732940.001]
  • [Cites] Palliat Med. 2002 May;16(3):213-8 [12046997.001]
  • [Cites] Hepatology. 2003 Jul;38(1):258-66 [12830009.001]
  • [Cites] N Engl J Med. 2004 Apr 15;350(16):1646-54 [15084697.001]
  • [Cites] Surgery. 1974 Feb;75(2):299-304 [4590763.001]
  • [Cites] Arch Intern Med. 1979 Feb;139(2):235 [434979.001]
  • [Cites] Am J Clin Oncol. 1982 Apr;5(2):167-72 [6178284.001]
  • [Cites] Br J Surg. 1982 Aug;69(8):441-2 [7049306.001]
  • [Cites] J Surg Oncol. 1982 Aug;20(4):238-42 [6180252.001]
  • [Cites] Br J Surg. 1983 Aug;70(8):478-81 [6871638.001]
  • [Cites] Br Med J (Clin Res Ed). 1984 Mar 10;288(6419):749-51 [6423061.001]
  • [Cites] Cancer. 1984 Nov 15;54(10):2226-30 [6207907.001]
  • [Cites] Cancer. 1985 May 1;55(9):1973-8 [3978577.001]
  • [Cites] Hepatology. 1985 May-Jun;5(3):403-7 [3888808.001]
  • [Cites] Cancer Treat Rev. 1985 Dec;12 Suppl B:23-32 [3833327.001]
  • [Cites] Ann Surg. 1986 Jun;203(6):644-51 [3718029.001]
  • [Cites] Hepatology. 1988 Sep-Oct;8(5):1104-9 [3417231.001]
  • [Cites] Adv Intern Med. 1990;35:365-73 [2405598.001]
  • [Cites] Ann Intern Med. 1990 Jun 15;112(12):889-91 [2187389.001]
  • [Cites] Eur J Cancer. 1991;27(2):121-5 [1827272.001]
  • [Cites] J Gastroenterol Hepatol. 1992 Mar-Apr;7(2):161-4 [1571498.001]
  • [Cites] Gastroenterology. 1992 Oct;103(4):1302-6 [1397889.001]
  • [Cites] Gynecol Oncol. 1992 Oct;47(1):102-9 [1427388.001]
  • [Cites] Cancer. 1993 Mar 15;71(6):2027-30 [7680276.001]
  • [Cites] N Engl J Med. 1994 Feb 3;330(5):337-42 [8277955.001]
  • [Cites] Am J Hosp Pharm. 1994 May 1;51(9):1184-92 [8042637.001]
  • [Cites] Ann Surg Oncol. 1994 Sep;1(5):378-81 [7531600.001]
  • [Cites] Hepatology. 1996 Jan;23(1):164-76 [8550036.001]
  • [Cites] Anticancer Res. 1995 Sep-Oct;15(5B):2201-6 [8572625.001]
  • [Cites] Br J Surg. 1996 Jan;83(1):6-14 [8653366.001]
  • [Cites] Eur J Surg Oncol. 1996 Jun;22(3):237-9 [8654603.001]
  • [Cites] Medsurg Nurs. 1995 Dec;4(6):468-71 [8696395.001]
  • [Cites] N Z Med J. 1997 Feb 14;110(1037):33-5 [9066565.001]
  • [Cites] Clin Cancer Res. 1998 Aug;4(8):1899-902 [9717817.001]
  • [Cites] J Pain Symptom Manage. 1998 Aug;16(2):96-101 [9737100.001]
  • [Cites] Am J Pathol. 1998 Oct;153(4):1249-56 [9777956.001]
  • [Cites] Gynecol Oncol. 1998 Dec;71(3):381-5 [9887235.001]
  • [Cites] Diagn Cytopathol. 2005 Nov;33(5):300-8 [16240400.001]
  • [Cites] Eur J Cancer. 2006 Mar;42(5):589-97 [16434188.001]
  • [Cites] Anticancer Res. 2006 Jan-Feb;26(1B):709-13 [16739342.001]
  • [Cites] Gastrointest Endosc. 2006 Dec;64(6):908-13 [17140897.001]
  • [Cites] Ann Surg Oncol. 2007 Aug;14(8):2348-57 [17505860.001]
  • [Cites] J Nippon Med Sch. 2007 Oct;74(5):355-8 [17965529.001]
  • [Cites] J Gastroenterol Hepatol. 2007 Dec;22(12):2161-6 [18031375.001]
  • [Cites] QJM. 2008 Feb;101(2):71-85 [18184668.001]
  • [Cites] Palliat Med. 1999 Sep;13(5):429-30 [10659116.001]
  • (PMID = 19700895.001).
  • [ISSN] 0975-4466
  • [Journal-full-title] Annals of Saudi medicine
  • [ISO-abbreviation] Ann Saudi Med
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Saudi Arabia
  • [Number-of-references] 55
  • [Other-IDs] NLM/ PMC3290049
  •  go-up   go-down


32. Lee MJ, Jeon ES, Lee JS, Cho M, Suh DS, Chang CL, Kim JH: Lysophosphatidic acid in malignant ascites stimulates migration of human mesenchymal stem cells. J Cell Biochem; 2008 May 15;104(2):499-510
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lysophosphatidic acid in malignant ascites stimulates migration of human mesenchymal stem cells.
  • Lysophosphatidic acid (LPA) is elevated in ascites of ovarian cancer patients and is involved in growth and invasion of ovarian cancer cells.
  • In the present study, we demonstrated that ascites from ovarian cancer patients and LPA increased migration of human MSCs.
  • The migration of MSCs induced by LPA and malignant ascites was completely abrogated by pretreatment with Ki16425, an antagonist of LPA receptors, and by silencing of endogenous LPA(1), but not LPA(2), with small interference RNA, suggesting a key role of LPA played in the malignant ascites-induced migration.
  • In addition, LPA and malignant ascites increased intracellular concentration of calcium in MSCs, and Ki16425 completely inhibited the elevation of intracellular calcium.
  • These results suggest that LPA is a crucial component of the malignant ascites which induce the migration of MSCs and elevation of intracellular calcium.
  • [MeSH-major] Ascites. Lysophospholipids / physiology. Mesenchymal Stromal Cells / cytology. Ovarian Neoplasms / pathology. Peritoneal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 Wiley-Liss, Inc.
  • (PMID = 18027882.001).
  • [ISSN] 1097-4644
  • [Journal-full-title] Journal of cellular biochemistry
  • [ISO-abbreviation] J. Cell. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Lysophospholipids; 22002-87-5 / lysophosphatidic acid; EC 3.6.5.2 / rhoA GTP-Binding Protein; SY7Q814VUP / Calcium
  •  go-up   go-down


33. Hamilton CA, Maxwell GL, Chernofsky MR, Bernstein SA, Farley JH, Rose GS: Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer. Gynecol Oncol; 2008 Dec;111(3):530-2
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer.
  • BACKGROUND: Malignant ascites often has a profound impact on the quality of life of patients with refractory ovarian cancer.
  • CASE: We present a case of an 88 year-old receiving home hospice care with refractory ovarian cancer and severe symptomatic ascites.
  • We performed a paracentesis and treated her with intraperitoneal bevacizumab with dramatic improvement in her ascites and the quality of her final weeks of life.
  • CONCLUSION: Intraperitoneal bevacizumab may be a useful tool in the palliation of malignant ascites and is worthy of further study.
  • [MeSH-minor] Aged, 80 and over. Antibodies, Monoclonal, Humanized. Ascites / drug therapy. Ascites / pathology. Ascites / surgery. Bevacizumab. Female. Humans. Infusions, Parenteral. Paracentesis

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18561992.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


34. Graziosi L, Bugiantella W, Cavazzoni E, Donini A: [Laparoscopic intraperitoneal hyperthermic perfusion in palliation of malignant ascites. Case report]. G Chir; 2009 May;30(5):237-9
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Laparoscopic intraperitoneal hyperthermic perfusion in palliation of malignant ascites. Case report].
  • [Transliterated title] Chemioipertermia intraperitoneale laparoscopica nel trattamento dell'ascite maligna. Case report.
  • Malignant ascites is a pathological condition, due to several abdominal and extra-abdominal neoplasms, representing a difficult challenge in treatment.
  • A 49-years old woman with malignant ascites, secondary to peritoneal localization of right pleural mesothelioma, underwent, after failure of medical therapy, laparoscopic intraperitoneal chemotherapy (with Cisplatin 25 mg/m2/L and Doxorubicin 7 mg/m2/L).
  • An important and lasting reduction of ascites and abdominal symptoms was documented till the exitus, due to pulmonary embolism after 11 months.
  • Laparoscopic intraperitoneal chemotherapy may be a good therapeutic option to palliative malignant ascites in patient not eligible for a radical cytoreductive treatment, but further investigations are needed to standardized dosage and perfusion procedure.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ascites / therapy. Chemotherapy, Cancer, Regional Perfusion. Laparoscopy. Mesothelioma / therapy. Palliative Care / methods. Peritoneal Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19505418.001).
  • [ISSN] 0391-9005
  • [Journal-full-title] Il Giornale di chirurgia
  • [ISO-abbreviation] G Chir
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


35. Patriti A, Cavazzoni E, Graziosi L, Pisciaroli A, Luzi D, Gullà N, Donini A: Successful palliation of malignant ascites from peritoneal mesothelioma by laparoscopic intraperitoneal hyperthermic chemotherapy. Surg Laparosc Endosc Percutan Tech; 2008 Aug;18(4):426-8
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful palliation of malignant ascites from peritoneal mesothelioma by laparoscopic intraperitoneal hyperthermic chemotherapy.
  • A variety of options have been proposed to treat malignant ascites but most of them have failed to reach a significant impact in terms of palliation.
  • Here we present a case of a 49-year-old woman with malignant ascites secondary to peritoneal spreading of a right pleural mesothelioma.
  • A dramatic reduction of ascites was documented in the postoperative period and the patient experienced complete abdominal symptom relief.
  • Ascites did not recur during a follow-up period of 6 months.
  • LHIPEC could be a good therapeutic option to palliate malignant ascites from mesothelioma in cases not eligible for a radical treatment.
  • [MeSH-major] Ascites / therapy. Chemotherapy, Cancer, Regional Perfusion / methods. Laparoscopy. Mesothelioma / pathology. Palliative Care. Peritoneal Neoplasms / pathology

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18716551.001).
  • [ISSN] 1534-4908
  • [Journal-full-title] Surgical laparoscopy, endoscopy & percutaneous techniques
  • [ISO-abbreviation] Surg Laparosc Endosc Percutan Tech
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


36. Ammouri L, Prommer EE: Palliative treatment of malignant ascites: profile of catumaxomab. Biologics; 2010;4:103-10

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Palliative treatment of malignant ascites: profile of catumaxomab.
  • Malignant ascites is the abnormal accumulation of fluid in the peritoneal cavity associated with several intrapelvic and intra-abdominal malignancies.
  • The development of ascites leads to significant symptoms and poor quality of life for the cancer patient.
  • The development of trifunctional antibodies, which attach to specific overexpressed surface markers on tumor cells, and trigger an immune response leading to cytoreductive effects, represents a new approach to the management of malignant ascites.
  • The purpose of this review is to highlight current therapies for malignant ascites and review data as to the effectiveness of a new trifunctional antibody, catumaxomab.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1999 Jan 1;85(1):178-87 [9921991.001]
  • [Cites] J Pain Symptom Manage. 2009 Sep;38(3):341-9 [19328648.001]
  • [Cites] Cancer Chemother Pharmacol. 1999;43 Suppl:S72-7 [10357563.001]
  • [Cites] Ann Surg Oncol. 1999 Jun;6(4):373-8 [10379858.001]
  • [Cites] J Immunol. 1999 Aug 1;163(3):1246-52 [10415020.001]
  • [Cites] Palliat Med. 1999 Sep;13(5):429-30 [10659116.001]
  • [Cites] Int J Oncol. 2000 Mar;16(3):445-54 [10675474.001]
  • [Cites] Ann Intern Med. 1978 May;88(5):635-8 [646247.001]
  • [Cites] Gastroenterology. 1992 Oct;103(4):1302-6 [1397889.001]
  • [Cites] Ann Intern Med. 1992 Aug 1;117(3):215-20 [1616215.001]
  • [Cites] Eur J Cancer. 1991;27(2):121-5 [1827272.001]
  • [Cites] J Surg Res. 1987 Feb;42(2):126-32 [2434730.001]
  • [Cites] Am J Surg. 1989 Dec;158(6):598-601 [2480068.001]
  • [Cites] Am Surg. 1989 Jul;55(7):445-9 [2742227.001]
  • [Cites] AJR Am J Roentgenol. 1988 May;150(5):1035-41 [3258703.001]
  • [Cites] Am J Clin Oncol. 1988 Feb;11(1):3-6 [3277373.001]
  • [Cites] Gastroenterology. 1988 Jun;94(6):1493-502 [3360270.001]
  • [Cites] J Hepatol. 1987 Aug;5(1):102-8 [3655306.001]
  • [Cites] Ann Surg. 1986 Jun;203(6):644-51 [3718029.001]
  • [Cites] Br J Surg. 1982 Aug;69(8):441-2 [7049306.001]
  • [Cites] JAMA. 1982 Feb 26;247(8):1164-6 [7057606.001]
  • [Cites] Ann Intern Med. 1982 Mar;96(3):358-64 [7059101.001]
  • [Cites] J Pain Symptom Manage. 1995 Apr;10(3):237-42 [7629417.001]
  • [Cites] Br J Surg. 1996 Jan;83(1):6-14 [8653366.001]
  • [Cites] Eur J Surg Oncol. 1996 Jun;22(3):237-9 [8654603.001]
  • [Cites] Hepatology. 1996 Sep;24(3):549-51 [8781322.001]
  • [Cites] Am J Gastroenterol. 1997 Apr;92(4):567-75 [9128301.001]
  • [Cites] Hepatology. 1998 Jan;27(1):264-72 [9425946.001]
  • [Cites] Clin Cancer Res. 1998 Aug;4(8):1899-902 [9717817.001]
  • [Cites] J Pain Symptom Manage. 1998 Aug;16(2):96-101 [9737100.001]
  • [Cites] Gynecol Oncol. 1998 Dec;71(3):381-5 [9887235.001]
  • [Cites] Palliat Med. 2000 Jan;14(1):62-4 [10717726.001]
  • [Cites] Br J Cancer. 2000 Jul;83(2):261-6 [10901380.001]
  • [Cites] Cancer Res. 2000 Oct 1;60(19):5334-9 [11034066.001]
  • [Cites] Palliat Med. 2002 May;16(3):213-8 [12046997.001]
  • [Cites] Can J Oncol. 1996 Nov;6(2):474-80 [12056099.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2003 Apr;15(2):59-72 [12708713.001]
  • [Cites] Cancer. 2003 Sep 1;98(5):1061-71 [12942576.001]
  • [Cites] J Am Coll Surg. 2004 Jun;198(6):999-1011 [15194082.001]
  • [Cites] Eur J Cancer. 2006 Mar;42(5):589-97 [16434188.001]
  • [Cites] Gynecol Oncol. 2006 May;101(2):360-2 [16499957.001]
  • [Cites] Cardiovasc Intervent Radiol. 2007 Mar-Apr;30(2):232-6 [17206391.001]
  • [Cites] Ann Oncol. 2007 May;18(5):945-9 [17298959.001]
  • [Cites] Clin Cancer Res. 2007 Jul 1;13(13):3899-905 [17606723.001]
  • [Cites] Cancer Treat Res. 2007;134:459-67 [17633074.001]
  • [Cites] Curr Opin Mol Ther. 2008 Jun;10(3):273-84 [18535935.001]
  • [Cites] Curr Treat Options Oncol. 2008 Jun;9(2-3):215-33 [18777213.001]
  • [Cites] J Immunother. 2009 Feb-Mar;32(2):195-202 [19238019.001]
  • [Cites] Histochem Cell Biol. 1999 Jan;111(1):13-21 [9930879.001]
  • (PMID = 20531969.001).
  • [ISSN] 1177-5491
  • [Journal-full-title] Biologics : targets & therapy
  • [ISO-abbreviation] Biologics
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC2880345
  • [Keywords] NOTNLM ; ascites / catumaxomab / trifunctional
  •  go-up   go-down


37. Garofalo A, Valle M, Garcia J, Sugarbaker PH: Laparoscopic intraperitoneal hyperthermic chemotherapy for palliation of debilitating malignant ascites. Eur J Surg Oncol; 2006 Aug;32(6):682-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic intraperitoneal hyperthermic chemotherapy for palliation of debilitating malignant ascites.
  • AIM: To report the use of laparoscopic Intraperitoneal Hyperthermic Chemotherapy (LIPHC) in the treatment of malignant ascites.
  • Ascites was from gastric cancer (5 cases), colorectal cancer (3 cases), ovarian cancer (3 cases), breast cancer (2 cases) and peritoneal mesothelioma (1 case).
  • RESULTS: Ascites was controlled in all the treated cases.
  • CONCLUSIONS: This method resulted in benefit for those peritoneal carcinomatosis patients with debilitating malignant ascites who were excluded from cytoreductive surgery.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ascites / drug therapy. Hyperthermia, Induced. Laparoscopy. Neoplasms / pathology. Palliative Care

  • MedlinePlus Health Information. consumer health - Palliative Care.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16631341.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


38. Buyukberber M, Koruk M, Savas MC, Gulsen MT, Pehlivan Y, Deveci R, Sevinc A, Gergerlioglu S: Leptin levels in the differential diagnosis between benign and malignant ascites. World J Gastroenterol; 2007 Jan 21;13(3):398-402

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leptin levels in the differential diagnosis between benign and malignant ascites.
  • AIM: To evaluate the role of leptin levels in the differential diagnosis of ascites.
  • METHODS: Ascitic leptin, TNFalpha and serum leptin levels were measured in 77 patients with ascites (35 with malignancies, 30 cirrhosis and 12 tuberculosis).
  • Peritoneal biopsy, ascites cytology and cultures or biochemical values were used for the diagnosis of patients.
  • RESULTS: In patients with malignancies, the mean serum and ascites leptin levels and their ratios were significantly decreased compared to the other patient groups and controls.
  • In tuberculosis peritonitis, ascitic fluid TNFalpha levels were significantly higher than malignant ascites and cirrhotic sterile ascites.
  • CONCLUSION: In patients with malignant ascites, levels of leptin and TNFalpha were significantly lower than in patients with tuberculous ascites.
  • [MeSH-major] Ascites / diagnosis. Leptin / metabolism
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Prospective Studies. Tumor Necrosis Factor-alpha / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Hepatol. 2000 Jul;33(1):33-7 [10905583.001]
  • [Cites] Leuk Lymphoma. 2006 Mar;47(3):565-8 [16396783.001]
  • [Cites] Horm Res. 1999;52(6):279-83 [10965207.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2001 May;13(5):581-5 [11396540.001]
  • [Cites] Gynecol Oncol. 2001 Nov;83(2):316-8 [11606091.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Feb;87(2):758-63 [11836317.001]
  • [Cites] Endocr Res. 2003 Aug;29(3):257-64 [14535627.001]
  • [Cites] J Viral Hepat. 2004 Jan;11(1):91-6 [14738564.001]
  • [Cites] Respirology. 2004 Mar;9(1):81-6 [14982607.001]
  • [Cites] Dig Dis Sci. 2004 Feb;49(2):275-80 [15104370.001]
  • [Cites] BMC Gastroenterol. 2004 Sep 23;4:23 [15387890.001]
  • [Cites] Br J Surg. 1973 Aug;60(8):646-9 [4541913.001]
  • [Cites] Med Sci Sports Exerc. 1980;12(3):175-81 [7402053.001]
  • [Cites] Hepatology. 1992 May;15(5):782-94 [1568718.001]
  • [Cites] N Engl J Med. 1996 Feb 1;334(5):292-5 [8532024.001]
  • [Cites] J Clin Invest. 1996 May 1;97(9):2152-7 [8621806.001]
  • [Cites] J Exp Med. 1997 Jan 6;185(1):171-5 [8996253.001]
  • [Cites] Eur J Med Res. 1997 Jan;2(1):7-13 [9049588.001]
  • [Cites] J Biol Chem. 1997 Mar 7;272(10):6093-6 [9102398.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Apr;82(4):1293-300 [9100610.001]
  • [Cites] J Clin Invest. 1997 Dec 1;100(11):2777-82 [9389742.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Dec;82(12):4080-2 [9398717.001]
  • [Cites] Hepatology. 1998 Feb;27(2):346-50 [9462629.001]
  • [Cites] Int J Cancer. 1998 Mar 30;76(1):25-8 [9533757.001]
  • [Cites] Hepatology. 1998 May;27(5):1227-32 [9581675.001]
  • [Cites] Alcohol Clin Exp Res. 1998 Aug;22(5 Suppl):231S-237S [9727642.001]
  • [Cites] Gastroenterology. 1998 Oct;115(4):947-53 [9753498.001]
  • [Cites] Nature. 1998 Oct 22;395(6704):763-70 [9796811.001]
  • [Cites] Int J Obes Relat Metab Disord. 1998 Dec;22(12):1234-8 [9877260.001]
  • [Cites] Int J Cancer. 1999 Feb 9;80(4):523-6 [9935151.001]
  • [Cites] Int J Obes Relat Metab Disord. 1999 Feb;23 Suppl 1:29-36 [10193859.001]
  • [Cites] Ann Intern Med. 1999 Apr 20;130(8):671-80 [10215564.001]
  • [Cites] Hepatology. 1999 Jun;29(6):1818-24 [10347125.001]
  • [Cites] J Natl Med Assoc. 2005 Jan;97(1):79-84 [15719876.001]
  • [Cites] J Hepatol. 2000 Jul;33(1):38-42 [10905584.001]
  • (PMID = 17230608.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Leptin; 0 / Tumor Necrosis Factor-alpha
  • [Other-IDs] NLM/ PMC4065894
  •  go-up   go-down


39. Tomiyama K, Takahashi M, Fujii T, Kunisue H, Kanaya Y, Maruyama S, Yokoyama N, Nakao A, Soda M, Shimizu N: Improved quality of life for malignant ascites patients by Denver peritoneovenous shunts. Anticancer Res; 2006 May-Jun;26(3B):2393-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved quality of life for malignant ascites patients by Denver peritoneovenous shunts.
  • BACKGROUND: Intractable ascites secondary to malignant disease deteriorates the patients' quality of life.
  • PATIENTS AND METHODS: Thirty-three patients, who had undergone Denver peritoneovenous shunt for the treatment of ascites associated with malignant tumor from May 1998 to February 2004, were retrospectively analyzed.
  • Thirteen patients needed no post-operative therapy for ascites, whereas 17 patients could tentatively remain at home or be discharged.
  • CONCLUSION: The Denver shunt for malignant ascites is useful in improving quality of life, if indications are selected properly.
  • [MeSH-major] Ascites / surgery. Neoplasms / pathology. Neoplasms / surgery. Peritoneovenous Shunt / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16821622.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


40. Ozkan O, Akinci D, Gocmen R, Cil B, Ozmen M, Akhan O: Percutaneous placement of peritoneal port-catheter in patients with malignant ascites. Cardiovasc Intervent Radiol; 2007 Mar-Apr;30(2):232-6
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Percutaneous placement of peritoneal port-catheter in patients with malignant ascites.
  • We report our experience with a radiologically placed peritoneal port-catheter in palliation of malignant ascites.
  • Port-catheters were successfully placed under ultrasonographic and fluoroscopic guidance in seven patients (five women, two men) who had symptomatic malignant ascites.
  • Minor complications such as ascitic fluid leakage from the peritoneal entry site, migration of the catheter tip to the right upper quadrant, and reversal of the port reservoir occurred in four patients.
  • In patients with symptomatic malignant ascites, a peritoneal port-catheter can provide palliation and eliminate multiple hospital visits for repeated paracentesis with high patency and low complication rates.
  • [MeSH-major] Ascites / etiology. Ascites / therapy. Drainage / methods. Neoplasms / complications. Palliative Care / methods. Peritoneal Cavity

  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17206391.001).
  • [ISSN] 0174-1551
  • [Journal-full-title] Cardiovascular and interventional radiology
  • [ISO-abbreviation] Cardiovasc Intervent Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


41. Keen A, Fitzgerald D, Bryant A, Dickinson HO: Management of drainage for malignant ascites in gynaecological cancer. Cochrane Database Syst Rev; 2010;(1):CD007794
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of drainage for malignant ascites in gynaecological cancer.
  • BACKGROUND: Most patients with advanced ovarian cancer and some patients with advanced endometrial cancer need repeated drainage for malignant ascites.
  • Guidelines to advise those involved in the drainage of ascites are usually produced locally and are generally not evidence-based but mainly based on clinicians' anecdotal evidence and experience.
  • OBJECTIVES: To evaluate the benefit and harms of different practices in the management of drains for malignant ascites in the care of women with advanced or recurrent gynaecological cancer.
  • SELECTION CRITERIA: We searched for randomised controlled trials (RCTs), quasi-RCTs and non-randomised studies that compared a range of interventions for management of multiple paracentesis in women with malignant ascites who had a confirmed histological diagnosis of gynaecological cancer.
  • AUTHORS' CONCLUSIONS: Since no relevant studies were identified, we are unable to make recommendations regarding the management of drains for malignant ascites in women with gynaecological cancer.
  • [MeSH-major] Ascites / therapy. Drainage / methods. Genital Neoplasms, Female / complications

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2005 Apr;16(4):640-7 [15684225.001]
  • [Cites] J Med Assoc Thai. 1999 Jan;82(1):15-9 [10087733.001]
  • [Cites] Eur J Cancer. 2006 Mar;42(5):589-97 [16434188.001]
  • [Cites] J Palliat Med. 2006 Dec;9(6):1264-70 [17187534.001]
  • [Cites] Ann Oncol. 2007 May;18(5):945-9 [17298959.001]
  • [Cites] Ann Surg Oncol. 2007 Aug;14(8):2348-57 [17505860.001]
  • [Cites] Ann Acad Med Singapore. 2008 Jul;37(7):621-2 [18695781.001]
  • [Cites] Curr Treat Options Oncol. 2008 Jun;9(2-3):215-33 [18777213.001]
  • [Cites] J Vasc Interv Radiol. 2008 Dec;19(12):1723-31 [18951041.001]
  • [Cites] Palliat Med. 2002 May;16(3):213-8 [12046997.001]
  • [Cites] Can J Oncol. 1996 Nov;6(2):474-80 [12056099.001]
  • [Cites] BMJ. 2003 Sep 6;327(7414):557-60 [12958120.001]
  • [Cites] J Am Coll Surg. 2004 Jun;198(6):999-1011 [15194082.001]
  • [Cites] J Vasc Interv Radiol. 2004 Oct;15(10):1129-31 [15466800.001]
  • [Cites] Am J Obstet Gynecol. 1981 Dec 1;141(7):843-5 [7315911.001]
  • [Cites] J Surg Oncol. 1982 Aug;20(4):238-42 [6180252.001]
  • [Cites] Br Med J (Clin Res Ed). 1984 Apr 7;288(6423):1041 [6423185.001]
  • [Cites] Ann Surg. 1986 Jun;203(6):644-51 [3718029.001]
  • [Cites] Control Clin Trials. 1986 Sep;7(3):177-88 [3802833.001]
  • [Cites] J Pak Med Assoc. 1991 Feb;41(2):38-40 [1902531.001]
  • [Cites] Am Fam Physician. 1997 Jun;55(8):2612 [9191450.001]
  • [Cites] J Clin Epidemiol. 1997 Jun;50(6):683-91 [9250266.001]
  • [Cites] J Pain Symptom Manage. 1998 Aug;16(2):96-101 [9737100.001]
  • [Cites] Palliat Med. 2006 Jan;20(1):1-2 [16482751.001]
  • (PMID = 20091648.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 32
  • [Other-IDs] NLM/ EMS58190; NLM/ PMC4170997
  •  go-up   go-down


42. Madaan S, Palit V, Gudgeon P, Biyani CS: Omental metastasis with malignant ascites: an unusual manifestation of prostatic adenocarcinoma. Can Urol Assoc J; 2007 Sep;1(3):288-90

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Omental metastasis with malignant ascites: an unusual manifestation of prostatic adenocarcinoma.
  • Omental metastasis with malignant ascites from prostatic adenocarcinoma is rare.
  • Three years later, he presented with ascites and an omental mass.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Urology. 1992 May;39(5):495-7 [1580050.001]
  • [Cites] Lymphology. 1990 Dec;23(4):183-6 [2077299.001]
  • [Cites] J Urol. 1973 Aug;110(2):232-4 [4722620.001]
  • [Cites] Urology. 2002 May;59(5):773 [11992926.001]
  • [Cites] Am J Med Sci. 2004 May;327(5):262-3 [15166746.001]
  • [Cites] Scand J Urol Nephrol. 2002;36(3):225-7 [12201941.001]
  • [Cites] Am J Med. 2001 Aug 15;111(3):245-6 [11545100.001]
  • [Cites] J Urol. 1968 Aug;100(2):183-7 [5658662.001]
  • (PMID = 18542809.001).
  • [ISSN] 1911-6470
  • [Journal-full-title] Canadian Urological Association journal = Journal de l'Association des urologues du Canada
  • [ISO-abbreviation] Can Urol Assoc J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2422958
  •  go-up   go-down


43. Ba MC, Cui SZ, Lin SQ, Tang YQ, Wu YB, Wang B, Zhang XL: Chemotherapy with laparoscope-assisted continuous circulatory hyperthermic intraperitoneal perfusion for malignant ascites. World J Gastroenterol; 2010 Apr 21;16(15):1901-7
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy with laparoscope-assisted continuous circulatory hyperthermic intraperitoneal perfusion for malignant ascites.
  • AIM: To investigate the procedure, feasibility and effects of laparoscope-assisted continuous circulatory hyperthermic intraperitoneal perfusion chemotherapy (CHIPC) in treatment of malignant ascites induced by peritoneal carcinomatosis from gastric cancers.
  • METHODS: From August 2006 to March 2008, the laparoscopic approach was used to perform CHIPC on 16 patients with malignant ascites induced by gastric cancer or postoperative intraperitoneal seeding.
  • Clinically complete remission of ascites and related symptoms were achieved in 14 patients, and partial remission was achieved in 2 patients.
  • CONCLUSION: Laparoscope-assisted CHIPC is a safe, feasible and effective procedure in the treatment of debilitating malignant ascites induced by unresectable gastric cancers.
  • [MeSH-major] Ascites / pathology. Chemotherapy, Cancer, Regional Perfusion / methods. Laparoscopy / methods. Peritoneal Neoplasms / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Surg Oncol. 2003 Jul;83(3):147-53 [12827682.001]
  • [Cites] In Vivo. 2009 Jan-Feb;23(1):187-90 [19368148.001]
  • [Cites] Gynecol Oncol. 2005 Nov;99(2):358-61 [16112182.001]
  • [Cites] Suppl Tumori. 2005 May-Jun;4(3):S122-3 [16437944.001]
  • [Cites] Cancer. 2006 Mar 1;106(5):1144-53 [16456817.001]
  • [Cites] J Gastrointest Surg. 2006 Jul-Aug;10(7):1038-43 [16843875.001]
  • [Cites] Eur J Surg Oncol. 2006 Aug;32(6):682-5 [16631341.001]
  • [Cites] Eur J Surg Oncol. 2006 Aug;32(6):625-7 [16822641.001]
  • [Cites] J Am Coll Surg. 2007 May;204(5):943-53; discussion 953-5 [17481516.001]
  • [Cites] Surg Oncol Clin N Am. 2007 Jul;16(3):653-66, x [17606199.001]
  • [Cites] Ann Surg Oncol. 2007 Nov;14(11):3274-82 [17653591.001]
  • [Cites] Ann Surg Oncol. 2008 Jan;15(1):339-44 [17943387.001]
  • [Cites] Eur J Surg Oncol. 2008 Feb;34(2):154-8 [17640844.001]
  • [Cites] Ann Surg Oncol. 2008 Feb;15(2):542-6 [17929098.001]
  • [Cites] World J Gastroenterol. 2008 Feb 28;14(8):1159-66 [18300340.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2008 Aug;18(4):426-8 [18716551.001]
  • [Cites] Eur J Surg Oncol. 2005 Jun;31(5):540-3 [15922890.001]
  • (PMID = 20397270.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2856833
  • [Keywords] NOTNLM ; Chemotherapy / Gastric cancer / Intraperitoneal hyperthermic perfusion / Laparoscopy / Malignant ascites
  •  go-up   go-down


44. Kobayashi M, Sakamoto J, Namikawa T, Okamoto K, Okabayashi T, Ichikawa K, Araki K: Pharmacokinetic study of paclitaxel in malignant ascites from advanced gastric cancer patients. World J Gastroenterol; 2006 Mar 7;12(9):1412-5
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacokinetic study of paclitaxel in malignant ascites from advanced gastric cancer patients.
  • AIM: To examine the paclitaxel concentrations in plasma and ascites after its intravenous administration in patients with ascites due to peritonitis carcinomatosa resulting from advanced gastric cancer.
  • METHODS: Two patients with ascites due to peritonitis carcinomatosa resulting from gastric cancer were included in this study.
  • The paclitaxel concentrations in plasma and ascites were investigated for 72 h in case 1 and 168 h in case 2 after intravenous administration.
  • In contrast,the paclitaxel concentration in ascites increased gradually for 24 h after administration to a level consistent with the level found in plasma.
  • After 24 h the level of paclitaxel in ascites and plasma became similar, with the optimal level being maintained up to 72 h following administration.
  • CONCLUSION: The concentration of paclitaxel in ascites is maintained within the optimal level for the treatment of cancer cells for up to 72 h after intravenous administration.
  • Paclitaxel is a promising drug for the treatment of malignant ascites of gastric cancer.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / pharmacokinetics. Ascites / metabolism. Paclitaxel / pharmacokinetics. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1992 Sep;10(9):1485-91 [1355523.001]
  • [Cites] J Natl Cancer Inst. 1990 Aug 1;82(15):1247-59 [1973737.001]
  • [Cites] N Engl J Med. 1995 Apr 13;332(15):1004-14 [7885406.001]
  • [Cites] J Clin Oncol. 1995 Dec;13(12):2961-7 [8523061.001]
  • [Cites] Cancer. 1996 Jan 1;77(1):14-8 [8630921.001]
  • [Cites] Cancer Treat Res. 1996;81:1-5 [8834570.001]
  • [Cites] Cancer. 1997 Mar 1;79(5):1022-30 [9041166.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2620-4 [9704711.001]
  • [Cites] Cancer. 1999 Jan 15;85(2):295-301 [10023695.001]
  • [Cites] Cancer. 1999 Jun 1;85(11):2347-51 [10357404.001]
  • [Cites] Am J Clin Oncol. 1999 Dec;22(6):580-6 [10597742.001]
  • [Cites] Br J Cancer. 2000 Aug;83(4):458-62 [10945491.001]
  • [Cites] Jpn J Clin Oncol. 2001 Jun;31(6):275-8 [11463806.001]
  • [Cites] Ann Oncol. 2001 Aug;12(8):1133-7 [11583196.001]
  • [Cites] Gan To Kagaku Ryoho. 2002 Sep;29(9):1643-6 [12355953.001]
  • [Cites] Gan To Kagaku Ryoho. 2003 Jan;30(1):129-32 [12557718.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Mar;77(3):1561-5 [6103535.001]
  • [Cites] Cancer Treat Rev. 1986 Dec;13(4):219-42 [3545463.001]
  • [Cites] Cancer Res. 1987 May 1;47(9):2486-93 [2882837.001]
  • [Cites] J Clin Oncol. 1987 Aug;5(8):1232-9 [2887641.001]
  • [Cites] Cancer Res. 1988 Jul 15;48(14):4093-100 [2898289.001]
  • [Cites] Cancer Res. 1989 Jun 15;49(12):3380-4 [2720692.001]
  • [Cites] Cancer Res. 1989 Aug 15;49(16):4640-7 [2568175.001]
  • [Cites] Cancer Chemother Pharmacol. 1990;25(6):389-94 [2311166.001]
  • [Cites] J Clin Oncol. 1995 Jan;13(1):180-90 [7799018.001]
  • (PMID = 16552811.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  • [Other-IDs] NLM/ PMC4124320
  •  go-up   go-down


45. Woopen H, Sehouli J: Current and future options in the treatment of malignant ascites in ovarian cancer. Anticancer Res; 2009 Aug;29(8):3353-9
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current and future options in the treatment of malignant ascites in ovarian cancer.
  • BACKGROUND: Malignant ascites is a frequent problem for ovarian carcinoma patients.
  • In this study, different treatment options for malignant ascites due to ovarian carcinoma were sought.
  • CONCLUSION: The treatment of malignant ascites keeps a demanding difficulty and requires further study especially on progressive free survival and overall survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ascites / therapy. Ovarian Neoplasms / drug therapy. Peritoneal Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19661355.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


46. Bouwman LH, Wiendels DR, Rebergen SA, Guicherit OR: [Chylous ascites]. Ned Tijdschr Geneeskd; 2009;153:B92
Genetic Alliance. consumer health - Chylous Ascites.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Chylous ascites].
  • [Transliterated title] Chyleuze ascites.
  • The CT scan revealed an extensive build-up of peritoneal and retroperitoneal fluid.
  • Laparotomy revealed chylous ascites in the abdominal cavity.
  • No cause of the chylous ascites was found.
  • Extensive diagnostics are indicated in adults with chylous ascites without a history of surgery as the most common cause of the condition in this group is malignant lymphoma.
  • [MeSH-major] Chylous Ascites / diagnosis. Parenteral Nutrition, Total

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20051146.001).
  • [ISSN] 1876-8784
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


47. Ströhlein MA, Heiss MM: The trifunctional antibody catumaxomab in treatment of malignant ascites and peritoneal carcinomatosis. Future Oncol; 2010 Sep;6(9):1387-94
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The trifunctional antibody catumaxomab in treatment of malignant ascites and peritoneal carcinomatosis.
  • Peritoneal carcinomatosis remains an unsolved medical problem in modern oncologic treatment.
  • Excruciating symptoms such as malignant ascites, ileus, nausea, vomiting, dyspnoea and pain deteriorate the quality of life for affected patients.
  • There is still no effective standard treatment for peritoneal carcinomatosis.
  • Intraperitoneal catumaxomab therapy was shown to be the first effective therapy against accumulation of malignant ascites in patients with peritoneal carcinomatosis of epithelial cancer, reducing the need of paracentesis and prolonging puncture-free survival.
  • This paper reviews the mode of action of catumaxomab and analyzes different fields of local immunotherapy in patients with peritoneal carcinomatosis.
  • Catumaxomab is discussed to be an outstanding option for local control and therapy of peritoneal carcinomatosis, which could be an optimal modular therapy in addition to systemic chemotherapy and surgical tumor resection.
  • [MeSH-major] Antibodies, Bispecific / therapeutic use. Antineoplastic Agents / therapeutic use. Ascites / drug therapy. Carcinoma / drug therapy. Peritoneal Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20919824.001).
  • [ISSN] 1744-8301
  • [Journal-full-title] Future oncology (London, England)
  • [ISO-abbreviation] Future Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Bispecific; 0 / Antineoplastic Agents; 0 / catumaxomab
  •  go-up   go-down


48. Geng M, Ma T, YeE ZB, Ji YB, Lou GY, Xi WQ, Jiang JS, Xia HQ, Li H: [In vitro chemo-sensitivity MTT assay guided intraperitoneal chemotherapy for malignant ascites]. Zhonghua Zhong Liu Za Zhi; 2006 Jun;28(6):460-3
Hazardous Substances Data Bank. DOCETAXEL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [In vitro chemo-sensitivity MTT assay guided intraperitoneal chemotherapy for malignant ascites].
  • OBJECTIVE: To evaluate the feasibility and efficacy of intraperitoneal chemotherapy for malignant ascites caused by different types of abdominal cancers guided by chemo-sensitivity methyl tetrojolium coloremetric (MTT) assay in vitro.
  • METHODS: Cancer cells in the malignant ascites were collected for MTT assay to determine the chemo-sensitivity.
  • The correlation between the results of MTT assay and the response of malignant ascites, the clinical features, Karnofsky performance score (KPS) and prognosis were analyzed.
  • RESULTS: MTT assay indicated that Taxotere (TXT) and Hydroxycamptothecin (HCPT) were the most effective to cancer cells in malignant ascites, and HCPT was mostly frequently used for intraperitoneal chemotherapy (56.9%).
  • Twenty-four patients showed response by intraperitoneal chemotherapy (complete response: 7; partial response: 17) with a slightly significant correlation between the results of MTT assay and response of malignant ascites (P = 0. 014).
  • The KPS of the responders was improved significantly (P < 0.001), and the response of malignant ascites to intraperitoneal chemotherapy was demostrated as an independent prognostic factor by multi-variate analysis in this series.
  • CONCLUSION: In vitro chemo-sensitivity MTT assay guided intraperitoneal chemotherapy for malignant ascites is simple, effective and safe, which can improve the KPS and prognosis of the responders.
  • [MeSH-major] Adenocarcinoma / drug therapy. Ascites / drug therapy. Camptothecin / analogs & derivatives. Stomach Neoplasms / drug therapy. Taxoids / therapeutic use

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17152496.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 0 / Taxoids; 15H5577CQD / docetaxel; 67656-30-8 / 10-hydroxycamptothecin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


49. Zhang W, Tong Q, Wang X, Wang Q, Li S: T lymphocyte subsets determination and DNA ploidy analysis in the differential diagnosis between benign and malignant ascites. Cancer Invest; 2009 Jan;27(1):67-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T lymphocyte subsets determination and DNA ploidy analysis in the differential diagnosis between benign and malignant ascites.
  • Differentiating malignant from benign ascites often leads to confusion and an inability to exclude its multitude of causes in many patients.
  • There were significant differences in T lymphocyte subsets between benign and malignant ascites.
  • For malignant ascites, the sensitivity of DNA aneuploid is 75.6%, the specificity is 79.0%, and the accuracy is 77.6%.
  • The results demonstrate that T lymphocyte subsets determination and DNA ploidy analysis can be used in the differential diagnosis between benign and malignant ascites.
  • [MeSH-major] Ascites / diagnosis. DNA, Neoplasm / genetics. Ploidies. T-Lymphocyte Subsets / immunology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Flow Cytometry. Humans. Male. Middle Aged. Polymerase Chain Reaction. Prospective Studies. Reproducibility of Results. Sensitivity and Specificity. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19160105.001).
  • [ISSN] 1532-4192
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


50. Bokemeyer C: Catumaxomab--trifunctional anti-EpCAM antibody used to treat malignant ascites. Expert Opin Biol Ther; 2010 Aug;10(8):1259-69
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Catumaxomab--trifunctional anti-EpCAM antibody used to treat malignant ascites.
  • IMPORTANCE OF THE FIELD: Malignant ascites is a sign of advanced tumour growth and is associated with significant morbidity and a poor prognosis with a median survival time of a few months.
  • Paracentesis is a recommended treatment for malignant ascites, but can cause complications, for example infections, injury of abdominal organs, persistent leakage of ascites, and haematoma/haemorrhage.
  • The European Medicines Agency (EMA) approved the use of a trifunctional bispecific antibody, catumaxomab (Removab), for the intraperitoneal (i.p.) treatment of malignant ascites in April 2009.
  • AREAS COVERED IN THIS REVIEW: This review describes the tailored preclinical and the clinical development of catumaxomab for the i.p. treatment of malignant ascites from 1998 to 2009.
  • [MeSH-major] Antibodies, Bispecific / therapeutic use. Antineoplastic Agents / therapeutic use. Ascites / drug therapy. Cell Adhesion Molecules / antagonists & inhibitors. Neoplasms / immunology

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20624115.001).
  • [ISSN] 1744-7682
  • [Journal-full-title] Expert opinion on biological therapy
  • [ISO-abbreviation] Expert Opin Biol Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Bispecific; 0 / Antigens, Neoplasm; 0 / Antineoplastic Agents; 0 / Cell Adhesion Molecules; 0 / EPCAM protein, human; 0 / catumaxomab
  •  go-up   go-down


51. Becker G, Galandi D, Blum HE: Malignant ascites: systematic review and guideline for treatment. Eur J Cancer; 2006 Mar;42(5):589-97
PubMed Health. DARE review .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant ascites: systematic review and guideline for treatment.
  • A guideline on the management of symptomatic malignant ascites by abdominal paracentesis, diuretics and peritoneovenous shunting, based on a systematic review of the literature is presented.
  • Peritoneovenous shunts can control ascites in patients with malignant ascites, but have to be balanced by the potential risks of this procedure.
  • The available data about diuretics in treatment of malignant ascites are controversial.
  • [MeSH-major] Ascites / therapy. Diuretics / therapeutic use. Neoplasms / therapy. Paracentesis / methods. Peritoneovenous Shunt / methods

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Surg Educ. 2007 Jan-Feb;64(1):4-9 [17320802.001]
  • (PMID = 16434188.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Practice Guideline; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Diuretics
  • [Number-of-references] 78
  •  go-up   go-down


52. Kitayama J, Ishigami H, Kaisaki S, Hidemura A, Kato M, Otani K, Kamei T, Soma D, Miyato H, Yamashita H, Nagawa H: Weekly intravenous and intraperitoneal paclitaxel combined with S-1 for malignant ascites due to advanced gastric cancer. Oncology; 2010;78(1):40-6
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Weekly intravenous and intraperitoneal paclitaxel combined with S-1 for malignant ascites due to advanced gastric cancer.
  • Malignant ascites caused by gastric cancer are chemotherapy resistant and carry a poor prognosis.
  • The efficacy of a regimen including intraperitoneal paclitaxel (PTX) was evaluated in 33 gastric cancer patients with ascetic fluid in the peritoneal cavity diagnosed with computed tomography (CT) scanning.
  • Ascites disappeared completely in 8 patients and were markedly reduced (to <3% of the original volume) in 4 of the 9 patients (44%) who initially had massive (>2,500 ml) ascites.
  • Weekly intravenous and intraperitoneal PTX combined with S-1 was highly effective in gastric cancer with malignant ascites.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Ascites / drug therapy. Peritoneal Neoplasms / drug therapy. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 S. Karger AG, Basel.
  • (PMID = 20197706.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


53. Facchiano E, Scaringi S, Kianmanesh R, Sabate JM, Castel B, Flamant Y, Coffin B, Msika S: Laparoscopic hyperthermic intraperitoneal chemotherapy (HIPEC) for the treatment of malignant ascites secondary to unresectable peritoneal carcinomatosis from advanced gastric cancer. Eur J Surg Oncol; 2008 Feb;34(2):154-8
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic hyperthermic intraperitoneal chemotherapy (HIPEC) for the treatment of malignant ascites secondary to unresectable peritoneal carcinomatosis from advanced gastric cancer.
  • AIMS: To review our experience of laparoscopic hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of malignant ascites from advanced gastric cancer in order to discuss benefits, problems and possible indications.
  • METHODS: From June 2000 to May 2003 laparoscopic approach was used to perform HIPEC on five patients affected by malignant ascites secondary to unresectable peritoneal carcinomatosis of gastric origin, in order to associate the benefits of a definitive palliation of ascites with a minimal invasiveness.
  • All patients had ascites related symptoms requiring iterative paracenteses.
  • RESULTS: Complete clinical regression of ascites and related symptoms was achieved in all the five patients treated.
  • CONCLUSIONS: Laparoscopic HIPEC appears to be a safe and effective procedure to treat debilitating malignant ascites from unresectable peritoneal carcinomatosis.
  • [MeSH-major] Ascites / therapy. Carcinoma / complications. Chemotherapy, Cancer, Regional Perfusion / methods. Laparoscopy. Palliative Care / methods. Peritoneal Neoplasms / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17640844.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


54. Guleng B, Tateishi K, Kanai F, Jazag A, Ohta M, Asaoka Y, Ijichi H, Tanaka Y, Imamura J, Ikenoue T, Fukushima Y, Morikane K, Miyagishi M, Taira K, Kawabe T, Omata M: Cancer-derived VEGF plays no role in malignant ascites formation in the mouse. World J Gastroenterol; 2005 Sep 21;11(35):5455-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer-derived VEGF plays no role in malignant ascites formation in the mouse.
  • AIM: Vascular endothelial growth factor (VEGF) is a potent mediator of peritoneal fluid accumulation following tumor progression.
  • This study investigated the role of VEGF secreted by cancerous cells in the formation of malignant ascites.
  • Malignant ascites formation in the mouse was analyzed by intraperitoneal injection of PancO2 cells expressing VEGF or with expression knockdown.
  • The volume of ascites following peritoneal expansion of the tumor in VEGF knockdown cells and control cells did not differ statistically in this in vivo study.
  • Moreover, the VEGF concentration in the ascites did not differ statistically.
  • CONCLUSION: Malignant ascites formation might be mediated by VEGF production in noncancerous tissues, such as stromal compartments.
  • An anti-VEGF strategy against malignant ascites could be applied to various tumors regardless of whether they secrete VEGF.
  • [MeSH-major] Ascites / etiology. Vascular Endothelial Growth Factor A / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16222736.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / RNA, Small Interfering; 0 / Vascular Endothelial Growth Factor A
  • [Other-IDs] NLM/ PMC4320353
  •  go-up   go-down


55. Koyama S: Coordinate cell-surface expression of matrix metalloproteinases and their inhibitors on cancer-associated myofibroblasts from malignant ascites in patients with gastric carcinoma. J Cancer Res Clin Oncol; 2005 Dec;131(12):809-14
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coordinate cell-surface expression of matrix metalloproteinases and their inhibitors on cancer-associated myofibroblasts from malignant ascites in patients with gastric carcinoma.
  • However, myofibroblastic invasion remains largely unexplored in malignant ascites.
  • Purpose of this study is to investigate the spatial localization or regulation of matrix metalloproteinases (MMP-2, -7 -9, MT1-MMP) and their inhibitors (TIMP-2 and -4) on myofibroblasts from malignant ascites in 20 patients with gastric carcinoma.
  • CONCLUSION: This study provides the presence of invasive myofibroblasts with activated MMPs in close association with MMPs+ and TIMPs+ cancer cells and tumor-infiltrating lymphocytes from malignant ascites, emphasizing the importance of molecular cross-talk in tumor-host microenvironment for cancer invasion, metastasis and progression.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16180025.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Matrix Metalloproteinase Inhibitors; 0 / Protease Inhibitors; 0 / Tissue Inhibitor of Metalloproteinases; 0 / tissue inhibitor of metalloproteinase-4; 127497-59-0 / Tissue Inhibitor of Metalloproteinase-2
  •  go-up   go-down


56. Toyokawa T, Sawada T, Muguruma K, Kim T, Kimura K, Inoue T, Yamashita Y, Yashiro M, Ohira M, Hirakawa K: [A case of advanced gastric cancer with malignant ascites responding to weekly paclitaxel therapy]. Gan To Kagaku Ryoho; 2006 Nov;33(11):1637-40
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced gastric cancer with malignant ascites responding to weekly paclitaxel therapy].
  • She was diagnosed with advanced gastric cancer that was inoperable due to peritoneal metastasis, so weekly paclitaxel (PTX) therapy was carried out.
  • After 2 courses, malignant ascites completely disappeared and bilateral hydronephrosis improved.
  • After 4 courses, no ascites or hydronephrosis were seen.
  • We also investigated the concentration of paclitaxel in ascites.
  • Two hours after intravenous injection of PTX, the concentration of PTX in ascites rose over the reported cytotoxic dose of PTX, and this available concentration was maintained after 48 hours.
  • Weekly paclitaxel therapy is suggested to be one of the safe and useful treatments for advanced gastric cancer with malignant ascites.
  • [MeSH-major] Adenocarcinoma, Scirrhous / drug therapy. Antineoplastic Agents, Phytogenic / administration & dosage. Ascites / drug therapy. Paclitaxel / administration & dosage. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Drug Administration Schedule. Female. Humans. Hydronephrosis / complications. Middle Aged. Peritoneal Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17108715.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


57. Ayantunde AA, Parsons SL: Pattern and prognostic factors in patients with malignant ascites: a retrospective study. Ann Oncol; 2007 May;18(5):945-9
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pattern and prognostic factors in patients with malignant ascites: a retrospective study.
  • BACKGROUND: Malignant ascites is a manifestation of end stage events in a variety of cancers and associated with a poor prognosis.
  • We evaluated the pattern of cancers causing malignant ascites and factors affecting survival.
  • PATIENTS AND METHODS: Patients coded with the International Classification of Diseases-9 coding system for malignant ascites over a 2-year period were reviewed.
  • Fifty-eight per cent of the patients had symptoms related to the ascites.
  • Fifty-four per cent of our patients presented with ascites at the initial diagnosis of their cancer.
  • The median survival following diagnosis of ascites was 5.7 months.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17298959.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Blood Proteins; 0 / Diuretics; 0 / Serum Albumin
  •  go-up   go-down


58. Lane D, Robert V, Grondin R, Rancourt C, Piché A: Malignant ascites protect against TRAIL-induced apoptosis by activating the PI3K/Akt pathway in human ovarian carcinoma cells. Int J Cancer; 2007 Sep 15;121(6):1227-37
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant ascites protect against TRAIL-induced apoptosis by activating the PI3K/Akt pathway in human ovarian carcinoma cells.
  • Ascites are commonly found in ovarian cancer patients with advanced disease and are rich in cellular components and growth-promoting factors.
  • The purpose of this study was to assess the effect of malignant ascites on TRAIL-induced apoptosis.
  • We demonstrate that malignant ascites obtained from women with advanced ovarian cancer protect tumor cells from TRAIL- and FasL-induced apoptosis but not against cisplatin-induced apoptosis.
  • This antiapoptotic effect was consistently found among different malignant ascites while nonmalignant peritoneal fluids or conditioned medium from TRAIL-resistant cells failed to protect tumor cells against TRAIL killing.
  • Malignant ascites strongly inhibits TRAIL-induced caspase-3 activation and PARP cleavage.
  • Furthermore, ascites activate PI3K and its downstream target Akt and increases c-FLIP(S) protein levels without affecting ERK phosphorylation status.
  • The antiapoptotic effect of malignant ascites is abrogated by the inhibition of PI3K with LY294002, by a specific inhibitor of Akt and by Akt siRNA.
  • We further show that the pro-survival effect of ascites can be suppressed by down-regulation of c-FLIP(S).
  • Our data indicate that malignant effusions protect against TRAIL-induced apoptosis by activating the PI3K/Akt pathway.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17534891.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / CASP8 and FADD-Like Apoptosis Regulating Protein; 0 / CFLAR protein, human; 0 / Chromones; 0 / Enzyme Inhibitors; 0 / Morpholines; 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / TNFSF10 protein, human; 154447-36-6 / 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


59. Seike M, Maetani I, Sakai Y: Treatment of malignant ascites in patients with advanced cancer: peritoneovenous shunt versus paracentesis. J Gastroenterol Hepatol; 2007 Dec;22(12):2161-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of malignant ascites in patients with advanced cancer: peritoneovenous shunt versus paracentesis.
  • BACKGROUND: Malignant ascites in patients with advanced cancer is often difficult to treat and effective palliation is not achieved.
  • METHODS: We performed peritoneovenous shunt (PVS) placement in patients with malignant ascites, who were admitted to our institution between January 2000 and March 2005.
  • CONCLUSIONS: PVS placement provides an effective treatment option for patients with refractory malignant ascites in advanced cancer, and yields a higher likelihood of discharge compared with conventional paracentesis.
  • [MeSH-major] Ascites / complications. Ascites / therapy. Neoplasms / complications. Neoplasms / therapy. Paracentesis / methods. Peritoneovenous Shunt / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18031375.001).
  • [ISSN] 0815-9319
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


60. Liu HL, Chen J: Oncolytic virus as an agent for the treatment of malignant ascites. Cancer Biother Radiopharm; 2009 Feb;24(1):99-102
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncolytic virus as an agent for the treatment of malignant ascites.
  • Taking the selective killing of peritoneally planted tumor cells by the oncolytic virus H101 as the rationale for the ascites treatment, we report in this paper the intraperitoneal H101 in 9 patients with malignant ascites.
  • Further, this report also highlights the potential of H101 in malignant ascites treatment.
  • [MeSH-major] Ascites / therapy. Oncolytic Virotherapy / methods. Oncolytic Viruses / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19216627.001).
  • [ISSN] 1557-8852
  • [Journal-full-title] Cancer biotherapy & radiopharmaceuticals
  • [ISO-abbreviation] Cancer Biother. Radiopharm.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


61. Shukuya T, Yasui H, Boku N, Onozawa Y, Fukutomi A, Yamazaki K, Taku K, Kojima T, Machida N: Weekly Paclitaxel after failure of gemcitabine in pancreatic cancer patients with malignant ascites: a retrospective study. Jpn J Clin Oncol; 2010 Dec;40(12):1135-8
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Weekly Paclitaxel after failure of gemcitabine in pancreatic cancer patients with malignant ascites: a retrospective study.
  • OBJECTIVES: Peritoneal metastasis is one of the major sites of disease progression of pancreatic cancer.
  • There have been few trials in the second-line setting after gemcitabine failure because patients can hardly be candidates for chemotherapy after failure in the first-line chemotherapy, especially those with malignant ascites.
  • The safety and efficacy of weekly paclitaxel therapy was evaluated for pancreatic cancer patients with malignant ascites in this retrospective study.
  • METHODS: The subjects of this retrospective study were 23 advanced pancreatic cancer patients with malignant ascites who received weekly paclitaxel therapy after gemcitabine failure.
  • RESULTS: While the disease control rate was 35%, decrease of ascites was obtained in 30% of the patients and ascites control rate was 61%.
  • CONCLUSIONS: Weekly paclitaxel therapy may be useful treatment option for pancreatic cancer patients with malignant ascites after gemcitabine failure.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Ascites / etiology. Deoxycytidine / analogs & derivatives. Paclitaxel / therapeutic use. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / pathology. Peritoneal Neoplasms / complications

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20656694.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


62. Kobold S, Hegewisch-Becker S, Oechsle K, Jordan K, Bokemeyer C, Atanackovic D: Intraperitoneal VEGF inhibition using bevacizumab: a potential approach for the symptomatic treatment of malignant ascites? Oncologist; 2009 Dec;14(12):1242-51
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraperitoneal VEGF inhibition using bevacizumab: a potential approach for the symptomatic treatment of malignant ascites?
  • Despite overall improvements in oncological care in the palliative setting, symptomatic malignant ascites remains a severe clinical problem.
  • This form of effusion is known to be widely resistant to established modes of systemic therapy.
  • Recently, the trifunctional monoclonal antibody catumaxomab given i.p. has shown symptom relief in patients with ovarian cancer and malignant ascites.
  • Accordingly, recent evidence suggests that targeting VEGF may have the potential to suspend the ascites production resulting from peritoneal metastasis.
  • Because such an effect would result in significant relief for patients, future clinical studies should stringently assess the effectiveness of this targeted therapy for the treatment of malignant i.p. effusions.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Ascites / drug therapy. Peritoneal Neoplasms / drug therapy. Vascular Endothelial Growth Factor A / antagonists & inhibitors

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20008305.001).
  • [ISSN] 1549-490X
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V / Bevacizumab
  • [Number-of-references] 122
  •  go-up   go-down


63. Yildirim B, Sari R, Isci N: Patients with spontaneous bacterial peritonitis, and malignant and cirrhotic ascites. J Natl Med Assoc; 2005 Feb;97(2):276-80
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patients with spontaneous bacterial peritonitis, and malignant and cirrhotic ascites.
  • BACKGROUND: Cytokines play a key role in the regulation of cells of the immune system and also have been implicated in the pathogenesis of malignant diseases.
  • METHOD AND PATIENTS: We studied tumor necrosis factor-alpha, tumor necrosis factor receptor and C-reactive protein levels in both ascitic fluid and serum in patients with spontaneous bacterial peritonitis (SBP) (n = 22), and in the malignant (n = 38) and cirrhotic (n = 32) ascites.
  • RESULTS: C-reactive protein, tumor necrosis factor-alpha and tumor necrosis factor receptor levels in the ascitic fluid were found to be elevated in the SBP (p < 0.001) and malignant groups (p < 0.005) when compared with the sterile cirrhotic group.
  • C-reactive protein levels in the serum were found to be elevated in the SBP group when compared with the sterile cirrhotic (p < 0.001) and malignant group (p < 0.005).
  • Tumor necrosis factor-alpha in the serum was significantly elevated in the SBP when compared with the cirrhotic (p < 0.005) and malignant ascites (p < 0.001).
  • Sensitivity and specificity of ascitic fluid CRP in discriminating malignant 84% and 67% and SBP from sterile ascites were 90% and 76%, respectively.
  • Sensitivity and specificity of ascitic fluid TNF-alpha in discriminating malignant 77% and 60% and SBP from sterile ascites were 82% and 66%, respectively.
  • Sensitivity and specificity of TNF-r p60 in discriminating malignant 74% and 70% and SBP from sterile ascites were 80% and 76%, respectively.
  • Ascitic fluid Creactive protein to differentiate SBP and malignant ascitic from cirrhotic ascites are cheap, practical and safe tests used in the differential diagnosis of ascites.
  • [MeSH-major] Ascites / blood. Ascitic Fluid / metabolism. C-Reactive Protein / metabolism. Liver Cirrhosis / blood. Liver Neoplasms / blood. Peritonitis / blood. Peritonitis / microbiology. Receptors, Tumor Necrosis Factor / metabolism. Tumor Necrosis Factor-alpha / metabolism

  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Intern Med. 1990 Jun 15;112(12):917-20 [2339855.001]
  • [Cites] Lancet. 1992 Jan 11;339(8785):89-91 [1345871.001]
  • [Cites] Adv Intern Med. 1992;37:313-36 [1558000.001]
  • [Cites] Immunol Today. 1992 Apr;13(4):122-5 [1580993.001]
  • [Cites] Hepatology. 1992 Sep;16(3):749-55 [1324217.001]
  • [Cites] Kidney Int. 1993 Jan;43(1):226-33 [8433563.001]
  • [Cites] Clin Infect Dis. 1993 Aug;17(2):218-23 [7980730.001]
  • [Cites] Cancer. 1993 Oct 15;72(8):2433-40 [8402460.001]
  • [Cites] Eur J Clin Invest. 1993 Dec;23(12):832-6 [7511536.001]
  • [Cites] Cytokine. 1995 Jan;7(1):26-38 [7749064.001]
  • [Cites] Liver. 1995 Oct;15(5):265-70 [8531597.001]
  • [Cites] Hepatology. 1998 May;27(5):1227-32 [9581675.001]
  • [Cites] J Pediatr. 1981 Sep;99(3):365-9 [7264788.001]
  • [Cites] Clin Exp Immunol. 1984 Jun;56(3):669-76 [6235072.001]
  • [Cites] Hepatology. 1985 May-Jun;5(3):457-62 [3888810.001]
  • [Cites] Dis Mon. 1985 Sep;31(9):1-48 [3899555.001]
  • [Cites] Am J Clin Pathol. 1986 Dec;86(6):773-5 [3788865.001]
  • [Cites] Gut. 1987 May;28(5):623-41 [3297941.001]
  • [Cites] J Exp Med. 1987 Jul 1;166(1):253-8 [2439635.001]
  • [Cites] J Exp Med. 1987 Oct 1;166(4):1132-7 [3309124.001]
  • [Cites] Lancet. 1988 Jul 9;2(8602):72-4 [2898700.001]
  • [Cites] Cancer. 1989 Apr 15;63(8):1567-71 [2466549.001]
  • [Cites] Surg Gynecol Obstet. 1990 Jan;170(1):32-8 [2294627.001]
  • [Cites] J Clin Invest. 1990 Nov;86(5):1396-1402 [2173717.001]
  • [Cites] Hepatology. 1991 Feb;13(2):364-75 [1995444.001]
  • [Cites] Semin Arthritis Rheum. 1990 Dec;20(3):129-47 [1705051.001]
  • [Cites] J Immunol. 1991 May 1;146(9):3032-7 [1707930.001]
  • [Cites] J Immunol. 1990 Oct 15;145(8):2507-13 [2170518.001]
  • (PMID = 15712792.001).
  • [ISSN] 1943-4693
  • [Journal-full-title] Journal of the National Medical Association
  • [ISO-abbreviation] J Natl Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines; 0 / Receptors, Tumor Necrosis Factor; 0 / Tumor Necrosis Factor-alpha; 9007-41-4 / C-Reactive Protein
  • [Other-IDs] NLM/ PMC2568775
  •  go-up   go-down


64. Hironaka K, Yamaguchi Y, Okita R, Okawaki M, Nagamine I: Essential requirement of toll-like receptor 4 expression on CD11c+ cells for locoregional immunotherapy of malignant ascites using a streptococcal preparation OK-432. Anticancer Res; 2006 Sep-Oct;26(5B):3701-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Essential requirement of toll-like receptor 4 expression on CD11c+ cells for locoregional immunotherapy of malignant ascites using a streptococcal preparation OK-432.
  • The involvement of TLRs in the action mechanism of OK-432, a bacterial preparation, was investigated in the locoregional treatment of malignant ascites from gastric cancer.
  • The expression of TLRs in ascites cells was analyzed using reverse-transcription polymerase chain reaction specific for TLRs and by flow cytometry using anti-TLR2, -TLR4, -CD4, -CD8, and -CD11c antibodies.
  • These measurements were compared with the locoregional response of OK-432 immunotherapy for malignant ascites, as well as TNF-alpha producing potential, which was measured by ELISA, of ascites cells stimulated in vitro with OK-432.
  • It was observed that OK-432 immunotherapy for malignant ascites showed 8 positive (67%) and 4 negative responses with the tolerable adverse effects of fever elevation and abdominal pain.
  • The TNF-alpha production of ascites cells by in vitro OK-432 stimulation was significantly higher in responder patients than in non-responders.
  • The clinical responses were correlated with the expression of the TLR4 gene of ascites cells.
  • The TNF-alpha-producing potential of ascites cells by in vitro OK-432 stimulation was dependent on the existence of a CD11c + TLR-4+ cell population in ascites cells.
  • OK-432 was highly stimulatory for TNF-alpha production of ascites cells compared with other biological response modifiers of PSK and LEM.
  • These results suggest that TLR-4 expression on ascites cells of a macrophage lineage is essential for ascites cells to produce TNF-alpha in relation to OK-432 stimulation and for subsequent positive clinical responses in locoregional immunotherapy using OK-432 for malignant ascites from gastric cancer.
  • [MeSH-major] Antigens, CD11c / metabolism. Ascites / therapy. Immunotherapy. Picibanil / therapeutic use. Stomach Neoplasms / therapy. Toll-Like Receptor 4 / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17094388.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, CD11c; 0 / DNA Primers; 0 / RNA, Messenger; 0 / TLR4 protein, human; 0 / Toll-Like Receptor 4; 0 / Tumor Necrosis Factor-alpha; 39325-01-4 / Picibanil
  •  go-up   go-down


65. Cai YJ, Zheng DY, Luo RC, Chen JZ, Li AM, Xi JL, Ding XM: [Avastin combined with cisplan inhibits malignant ascites production in nude mice bearing transplanted ovary carcinoma with high VEGF expression]. Nan Fang Yi Ke Da Xue Xue Bao; 2007 May;27(5):647-9
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Avastin combined with cisplan inhibits malignant ascites production in nude mice bearing transplanted ovary carcinoma with high VEGF expression].
  • OBJECTIVE: To establish a nude mouse model of malignant ascites with human ovarian carcinoma cell line OVCAR3 which highly expresses VEGF and evaluate the therapeutic of Avastin combined with cisplan.
  • METHODS: Forty-eight nude mice with malignant ascites resulting from intraperitoneal transplantation of human ovarian carcinoma cell line OVCAR3 were treated with intraperitoneal injection of Avastin, cisplan, their combination, and PBS, respectively, to observe the effect on ascites development, VEGF content in the ascites, peritoneal permeability, development of new vessels and number of tumor cells in the ascites.
  • RESULTS: Avastin obviously inhibited ascites accumulation and peritoneal capillary permeability, reduced VEGF protein level and microvascular density in the tumor tissues and the number of red cells and tumor cells in the malignant ascites, and prolonged the survival of the mice.
  • CONCLUSION: The bio-chemotherapeutic strategy with Avastin combined with cisplan can be a promising method for treatment of malignant ascites.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ascites / prevention & control. Ovarian Neoplasms / complications. Vascular Endothelial Growth Factor A / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17545079.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V / Bevacizumab; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


66. Komachi M, Tomura H, Malchinkhuu E, Tobo M, Mogi C, Yamada T, Kimura T, Kuwabara A, Ohta H, Im DS, Kurose H, Takeyoshi I, Sato K, Okajima F: LPA1 receptors mediate stimulation, whereas LPA2 receptors mediate inhibition, of migration of pancreatic cancer cells in response to lysophosphatidic acid and malignant ascites. Carcinogenesis; 2009 Mar;30(3):457-65
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] LPA1 receptors mediate stimulation, whereas LPA2 receptors mediate inhibition, of migration of pancreatic cancer cells in response to lysophosphatidic acid and malignant ascites.
  • Malignant ascites from pancreatic cancer patients has been reported to stimulate migration of pancreatic cancer cells through lysophosphatidic acid (LPA) and LPA(1) receptors.
  • Indeed, ascites- and LPA-induced migration was inhibited by Ki16425, an LPA(1) and LPA(3) antagonist, in Panc-1 cells.
  • Unexpectedly, however, in the presence of Ki16425, ascites and LPA inhibited cell migration in response to epidermal growth factor (EGF).
  • The inhibitory migratory response to ascites and LPA was also observed in the cells treated with pertussis toxin (PTX), a G(i) protein inhibitor, and attenuated by a small interfering RNA (siRNA) specific to the LPA(2) receptor.
  • [MeSH-major] Ascites / metabolism. Cell Movement / drug effects. Lysophospholipids / pharmacology. Pancreatic Neoplasms / metabolism. Receptors, Lysophosphatidic Acid / physiology

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19129242.001).
  • [ISSN] 1460-2180
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 3-(4-(4-((1-(2-chlorophenyl)ethoxy)carbonyl amino)-3-methyl-5-isoxazolyl) benzylsulfanyl) propanoic acid; 0 / Drug Combinations; 0 / Isoxazoles; 0 / Laminin; 0 / Lysophospholipids; 0 / Propionates; 0 / Proteoglycans; 0 / RNA, Small Interfering; 0 / Receptors, Lysophosphatidic Acid; 119978-18-6 / matrigel; 22002-87-5 / lysophosphatidic acid; 62229-50-9 / Epidermal Growth Factor; 9007-34-5 / Collagen; EC 2.4.2.31 / Pertussis Toxin; EC 3.6.5.1 / GTP-Binding Protein alpha Subunits, Gi-Go; EC 3.6.5.2 / rhoA GTP-Binding Protein
  •  go-up   go-down


67. Bellati F, Napoletano C, Ruscito I, Pastore M, Pernice M, Antonilli M, Nuti M, Benedetti Panici P: Complete remission of ovarian cancer induced intractable malignant ascites with intraperitoneal bevacizumab. Immunological observations and a literature review. Invest New Drugs; 2010 Dec;28(6):887-94
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete remission of ovarian cancer induced intractable malignant ascites with intraperitoneal bevacizumab. Immunological observations and a literature review.
  • Malignant ascites resistant to conventional drugs frequently affects ovarian cancer patients at the end of life.
  • Here we report the case of a patient who benefited from complete resolution of ascites after low dose intraperitoneal administration of bevacizumab.
  • Intraperitoneal administration induces an immune activation and appears promising in the treatment of malignant ascites.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Ascites / drug therapy. Ascites / immunology. Ovarian Neoplasms / complications

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19936983.001).
  • [ISSN] 1573-0646
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


68. Bar-Sela G, Goldberg H, Beck D, Amit A, Kuten A: Reducing malignant ascites accumulation by repeated intraperitoneal administrations of a Viscum album extract. Anticancer Res; 2006 Jan-Feb;26(1B):709-13

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reducing malignant ascites accumulation by repeated intraperitoneal administrations of a Viscum album extract.
  • BACKGROUND: Malignant ascites is a major problem in the management of advanced stages of certain malignancies.
  • The possibility of reducing the accumulation of ascites by intraperitoneal injections of a Viscum album extract (Iscador M) was evaluated.
  • PATIENTS AND METHODS: Twenty-three patients, with end-stage malignancies of varying histology, requiring repeated peritoneal punctures, were eligible for analysis.
  • CONCLUSION: This phase II study suggests that installation of Iscador M into the peritoneal cavity may reduce the need for repeated punctures.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Ascites / drug therapy. Neoplasms / pathology. Plant Extracts / therapeutic use. Plant Proteins / therapeutic use. Viscum album

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16739342.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Plant Extracts; 0 / Plant Proteins; 0 / viscum album peptide
  •  go-up   go-down


69. Valle M, Van der Speeten K, Garofalo A: Laparoscopic hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) in the management of refractory malignant ascites: A multi-institutional retrospective analysis in 52 patients. J Surg Oncol; 2009 Sep 15;100(4):331-4
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) in the management of refractory malignant ascites: A multi-institutional retrospective analysis in 52 patients.
  • Malignant ascites is a debilitating condition affecting cancer patients in their terminal stage of disease.
  • Laparoscopic HIPEC is a safe and effective method for palliating malignant ascites.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ascites / therapy. Chemotherapy, Cancer, Regional Perfusion. Drug Resistance, Neoplasm. Laparoscopy. Neoplasms / drug therapy. Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19697441.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


70. Yang W, Toffa SE, Lohn JW, Seifalian AM, Winslet MC: Malignant ascites increases the antioxidant ability of human ovarian (SKOV-3) and gastric adenocarcinoma (KATO-III) cells. Gynecol Oncol; 2005 Feb;96(2):430-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant ascites increases the antioxidant ability of human ovarian (SKOV-3) and gastric adenocarcinoma (KATO-III) cells.
  • (3) malignant ascites.
  • RESULTS: The results showed that the cancer cells were rendered resistant to oxidative stress and with upregulated CD44 gene expression by components of malignant ascites.
  • CONCLUSIONS: These findings suggest that malignant ascites increases the antioxidant ability of cancer cells and the potential of adhesion and invasion.
  • Thus, determination of the nature of these putative tumor-protective components of ascites may provide targets for therapeutic intervention.
  • [MeSH-major] Adenocarcinoma / metabolism. Antioxidants / metabolism. Ascites / metabolism. Ovarian Neoplasms / metabolism. Stomach Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MALONALDEHYDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15661232.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Antioxidants; 4Y8F71G49Q / Malondialdehyde; 5072-26-4 / Buthionine Sulfoximine; GAN16C9B8O / Glutathione
  •  go-up   go-down


71. Zheng R, Yano S, Zhang H, Nakataki E, Tachibana I, Kawase I, Hayashi S, Sone S: CD9 overexpression suppressed the liver metastasis and malignant ascites via inhibition of proliferation and motility of small-cell lung cancer cells in NK cell-depleted SCID mice. Oncol Res; 2005;15(7-8):365-72
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD9 overexpression suppressed the liver metastasis and malignant ascites via inhibition of proliferation and motility of small-cell lung cancer cells in NK cell-depleted SCID mice.
  • Parental and mock-transfected OS3-R5 cells developed liver metastasis and malignant ascites when they were intravenously inoculated into NK cell-depleted SCID mice.
  • CD9 gene transfection into OS3-R5 cells caused suppression of the liver metastasis and malignant ascites.
  • [MeSH-major] Antigens, CD / biosynthesis. Ascites / pathology. Carcinoma, Small Cell / secondary. Liver Neoplasms / secondary. Lung Neoplasms / pathology. Membrane Glycoproteins / biosynthesis

  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16491954.001).
  • [ISSN] 0965-0407
  • [Journal-full-title] Oncology research
  • [ISO-abbreviation] Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD9; 0 / CD9 protein, human; 0 / Cd9 protein, mouse; 0 / Membrane Glycoproteins
  •  go-up   go-down


72. Wang GQ, Xu JR, Wang R, Li HX, Xu N, Du XB, Wei YQ: [Inhibitory effect of mesenchymal stem cells carrying murine beta defensin 2 on malignant ascites in mice]. Ai Zheng; 2006 Jun;25(6):657-62
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Inhibitory effect of mesenchymal stem cells carrying murine beta defensin 2 on malignant ascites in mice].
  • This study was to develop a set of MBD2-lentivirus system, and observe its inhibitory effect on malignant ascites in mice.
  • Ascites status and survival status of the mice were observed.
  • The volume of tumor ascites was significantly less in MBD2-MSC group than in NS group, MSC group, and Null group [(3.0+/-1.0) ml vs. (10.8+/-1.0) ml, (10.2+/-1.3) ml, and (9.8+/-1.6) ml, P<0.05].
  • CONCLUSION: MBD2-lentivirus gene therapy system is constructed successfully, and can inhibit the formation of malignant ascites.
  • [MeSH-major] Ascites / therapy. Fibrosarcoma / complications. Mesenchymal Stem Cell Transplantation. Mesenchymal Stromal Cells / metabolism. beta-Defensins / biosynthesis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16764757.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Defb2 protein, mouse; 0 / Recombinant Proteins; 0 / beta-Defensins
  •  go-up   go-down


73. Wang GP, Guan YS, Jin XR, Jiang SS, Lu ZJ, Wu Y, Li Y, Li M, Luo F: Development of novel 5-fluorouracil carrier erythrocyte with pharmacokinetics and potent antitumor activity in mice bearing malignant ascites. J Gastroenterol Hepatol; 2010 May;25(5):985-90
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of novel 5-fluorouracil carrier erythrocyte with pharmacokinetics and potent antitumor activity in mice bearing malignant ascites.
  • BACKGROUND: To investigate pharmacokinetics and potency of antitumor activity of a novel 5-fluorouracil carrier erythrocyte (RBC-FU) in mice bearing malignant ascites.
  • After a H22 hepatocarcinoma malignant ascites model was established in Kunming mice, 5-FU encapsulated by carrier erythrocytes (for Group A) and 5-FU solution (for Group B) at 20 mg per kg were injected into the peritoneal cavity of the mice, respectively.
  • Blood and ascites samples were collected at different times to detect 5-FU quantity by HPLC.
  • In Group A, the maximum concentration (Cmax) and the area under curve (AUC) in peritoneal exudates were significantly higher than those of Group B (P < 0.05).
  • On the other hand, 5-FU level in serum was significantly lower than that in peritoneal exudates of Group A and B (P < 0.05).
  • Compared with that in Group B and the control, the quantity of malignant ascites in Group A had significant regression and the survival time was prolonged.
  • CONCLUSION: The hyperosmotic method described here could be suitable for producing this novel RBC-FU as a liposomal drug of potential value for treating malignant ascites by intraperitoneal administration.
  • [MeSH-major] Antimetabolites, Antineoplastic / blood. Antimetabolites, Antineoplastic / pharmacology. Drug Carriers. Erythrocyte Transfusion. Erythrocytes / metabolism. Fluorouracil / blood. Fluorouracil / pharmacology. Liver Neoplasms / drug therapy. Peritoneal Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20546454.001).
  • [ISSN] 1440-1746
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Carriers; 0 / Liposomes; U3P01618RT / Fluorouracil
  •  go-up   go-down


74. Runz S, Keller S, Rupp C, Stoeck A, Issa Y, Koensgen D, Mustea A, Sehouli J, Kristiansen G, Altevogt P: Malignant ascites-derived exosomes of ovarian carcinoma patients contain CD24 and EpCAM. Gynecol Oncol; 2007 Dec;107(3):563-71
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant ascites-derived exosomes of ovarian carcinoma patients contain CD24 and EpCAM.
  • METHODS: We used CD24 transfected carcinoma cell lines, ovarian carcinoma cell lines and malignant ascites fluid of ovarian carcinoma patients.
  • CD24 was also identified in exosomes isolated from ascites fluid of ovarian carcinoma patients.
  • The ascites exosomes contain gelatinolytic enzymes.
  • CONCLUSIONS: Our study identifies CD24 and EpCAM as cargo proteins of exosomes of cultured cell lines and malignant ascites.
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Ascites / metabolism. Cell Line, Tumor. Female. Humans. Lung Neoplasms / genetics. Lung Neoplasms / metabolism. Lung Neoplasms / pathology. Matrix Metalloproteinase 2 / metabolism. Matrix Metalloproteinase 9 / metabolism. Transfection

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17900673.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD24; 0 / Antigens, Neoplasm; 0 / CD24 protein, human; 0 / Cell Adhesion Molecules; 0 / EPCAM protein, human; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


75. Sako A, Kitayama J, Shida D, Suzuki R, Sakai T, Ohta H, Nagawa H: Lysophosphatidic acid (LPA)-induced vascular endothelial growth factor (VEGF) by mesothelial cells and quantification of host-derived VEGF in malignant ascites. J Surg Res; 2006 Jan;130(1):94-101
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lysophosphatidic acid (LPA)-induced vascular endothelial growth factor (VEGF) by mesothelial cells and quantification of host-derived VEGF in malignant ascites.
  • Malignant ascites contains high levels of LPA as well as vascular endothelial growth factor (VEGF).
  • Therefore, we evaluated the effect of LPA specifically on peritoneal mesothelial cells (PMC), and assessed another aspect of LPA in tumor biology mediated through the host cells.
  • Next, we quantified human- and mouse-VEGF separately in ascitic fluid of nude mice inoculated intraperitoneally with a human gastric cancer, MKN45, and thus evaluated the ratio of host-derived VEGF in malignant ascites.
  • CONCLUSION: Because tumor growth is often associated with an increase of LPA concentration in ascites, stimulation of VEGF production in PMC might have an important role in the growth of cancer cells disseminated in the peritoneal cavity.
  • [MeSH-major] Ascites / metabolism. Lysophospholipids / metabolism. Lysophospholipids / pharmacology. Stomach Neoplasms / physiopathology. Vascular Endothelial Growth Factor A / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16171822.001).
  • [ISSN] 0022-4804
  • [Journal-full-title] The Journal of surgical research
  • [ISO-abbreviation] J. Surg. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 3-(4-(4-((1-(2-chlorophenyl)ethoxy)carbonyl amino)-3-methyl-5-isoxazolyl) benzylsulfanyl) propanoic acid; 0 / Culture Media, Conditioned; 0 / Isoxazoles; 0 / Lysophospholipids; 0 / Propionates; 0 / RNA, Messenger; 0 / Receptors, Lysophosphatidic Acid; 0 / Vascular Endothelial Growth Factor A; 22002-87-5 / lysophosphatidic acid; EC 2.4.2.31 / Pertussis Toxin
  •  go-up   go-down


76. Fleming ND, Alvarez-Secord A, Von Gruenigen V, Miller MJ, Abernethy AP: Indwelling catheters for the management of refractory malignant ascites: a systematic literature overview and retrospective chart review. J Pain Symptom Manage; 2009 Sep;38(3):341-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Indwelling catheters for the management of refractory malignant ascites: a systematic literature overview and retrospective chart review.
  • The safety and efficacy of indwelling intraperitoneal (IP) catheters for the management of refractory malignant ascites is unclear.
  • A systematic literature overview and retrospective chart review of patients with malignant refractory ascites who underwent indwelling IP catheter placement was performed.
  • Tenckhoff (Quinton Instrument Company, Seattle, WA, USA), Pleurex (Denver Biomedical Inc., Golden, CO, USA), and peritoneal catheters were used, along with IP ports.
  • Median time from diagnosis to catheter placement was 25 months (range: 1-77).
  • In these retrospective studies, indwelling IP catheters appear to be a safe and effective palliative strategy to manage refractory malignant ascites, without overwhelming infection rates.
  • [MeSH-major] Ascites / therapy. Catheters, Indwelling

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19328648.001).
  • [ISSN] 1873-6513
  • [Journal-full-title] Journal of pain and symptom management
  • [ISO-abbreviation] J Pain Symptom Manage
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 24
  •  go-up   go-down


77. Elliott RL, Head JF: Complete resolution of malignant ascites in stage IV breast cancer by peritoneal drainage and innovative chemoimmunotherapy: a case report. Cancer Biother Radiopharm; 2006 Apr;21(2):138-45
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete resolution of malignant ascites in stage IV breast cancer by peritoneal drainage and innovative chemoimmunotherapy: a case report.
  • Malignant ascites is a very serious and difficult to manage problem in the cancer patient.
  • Numerous methods for managing the problem have been attempted, but few have afforded complete remission of the ascites with improved survival.
  • We are reporting a case of complete remission of malignant ascites in a stage IV breast cancer patient.
  • Her condition was managed by a peritoneal dialysis catheter and an aggressive intraperitoneal innovative chemoimmunotherapy protocol.
  • [MeSH-major] Ascites / therapy. Breast Neoplasms / therapy

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16706634.001).
  • [ISSN] 1084-9785
  • [Journal-full-title] Cancer biotherapy & radiopharmaceuticals
  • [ISO-abbreviation] Cancer Biother. Radiopharm.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


78. Heiss MM, Murawa P, Koralewski P, Kutarska E, Kolesnik OO, Ivanchenko VV, Dudnichenko AS, Aleknaviciene B, Razbadauskas A, Gore M, Ganea-Motan E, Ciuleanu T, Wimberger P, Schmittel A, Schmalfeldt B, Burges A, Bokemeyer C, Lindhofer H, Lahr A, Parsons SL: The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial. Int J Cancer; 2010 Nov 01;127(9):2209-21
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial.
  • Malignant ascites is a common manifestation of advanced cancers, and treatment options are limited.
  • The trifunctional antibody catumaxomab (anti-epithelial cell-adhesion molecule x anti-CD3) represents a targeted immunotherapy for the intraperitoneal (i.p.) treatment of malignant ascites secondary to epithelial cancers.
  • In this phase II/III trial (EudraCT 2004-000723-15; NCT00836654), cancer patients (n = 258) with recurrent symptomatic malignant ascites resistant to conventional chemotherapy were randomized to paracentesis plus catumaxomab (catumaxomab) or paracentesis alone (control) and stratified by cancer type (129 ovarian and 129 nonovarian).
  • Secondary efficacy parameters included time to next paracentesis, ascites signs and symptoms and overall survival (OS).
  • In addition, catumaxomab patients had fewer signs and symptoms of ascites than control patients.
  • Catumaxomab showed a clear clinical benefit in patients with malignant ascites secondary to epithelial cancers, especially gastric cancer, with an acceptable safety profile.
  • [MeSH-major] Antibodies, Bispecific / therapeutic use. Ascites / complications. Ascites / drug therapy. Neoplasms, Glandular and Epithelial / complications. Neoplasms, Glandular and Epithelial / drug therapy

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 2006 Mar;42(5):589-97 [16434188.001]
  • [Cites] Cancer Res. 2001 May 15;61(10):4105-11 [11358833.001]
  • [Cites] Ann Oncol. 2007 May;18(5):945-9 [17298959.001]
  • [Cites] Clin Cancer Res. 2007 Jul 1;13(13):3899-905 [17606723.001]
  • [Cites] Cancer Treat Res. 2007;134:109-18 [17633049.001]
  • [Cites] Br J Cancer. 2007 Aug 6;97(3):315-21 [17622246.001]
  • [Cites] Gynecol Oncol. 2008 Dec;111(3):530-2 [18561992.001]
  • [Cites] Gynecol Oncol. 2008 Dec;111(3):527-9 [18710781.001]
  • [Cites] Oncology. 2001;61(3):192-6 [11574774.001]
  • [Cites] Blood. 2001 Oct 15;98(8):2526-34 [11588051.001]
  • [Cites] Int J Cancer. 2002 Sep 10;101(2):183-9 [12209996.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2003 Apr;15(2):59-72 [12708713.001]
  • [Cites] Clin Cancer Res. 2003 Sep 1;9(10 Pt 2):4013S-21S [14506202.001]
  • [Cites] Hum Pathol. 2004 Jan;35(1):122-8 [14745734.001]
  • [Cites] Ann Surg. 1986 Jun;203(6):644-51 [3718029.001]
  • [Cites] Eur J Cancer. 1991;27(2):121-5 [1827272.001]
  • [Cites] Cytopathology. 1992;3(2):111-7 [1617160.001]
  • [Cites] Cancer. 1993 Mar 15;71(6):2027-30 [7680276.001]
  • [Cites] Transplant Proc. 1993 Apr;25(2 Suppl 1):16-20 [8465415.001]
  • [Cites] Diagn Cytopathol. 1993 Oct;9(5):516-21 [8287759.001]
  • [Cites] Eur J Cancer Care (Engl). 1995 Dec;4(4):178-83 [8548140.001]
  • [Cites] Br J Surg. 1996 Jan;83(1):6-14 [8653366.001]
  • [Cites] Gynecol Oncol. 1997 Jan;64(1):80-7 [8995552.001]
  • [Cites] Eur J Surg Oncol. 1997 Dec;23(6):526-31 [9484924.001]
  • [Cites] J Pain Symptom Manage. 1998 Aug;16(2):96-101 [9737100.001]
  • [Cites] Anticancer Res. 1998 Sep-Oct;18(5D):3917-25 [9854504.001]
  • [Cites] Int J Cancer. 1999 Feb 19;84(1):62-8 [9988234.001]
  • [Cites] Blood. 1999 Oct 1;94(7):2217-24 [10498591.001]
  • [Cites] Tohoku J Exp Med. 2005 May;206(1):31-40 [15802873.001]
  • [Cites] Am J Ther. 2005 May-Jun;12(3):254-61 [15891270.001]
  • [Cites] Int J Cancer. 2005 Nov 10;117(3):435-43 [15906359.001]
  • [Cites] Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6862-7 [16203775.001]
  • [Cites] N Engl J Med. 2006 Jan 5;354(1):34-43 [16394300.001]
  • [Cites] Br J Cancer. 2000 Jan;82(2):472-9 [10646907.001]
  • [Cites] Br J Cancer. 2000 Jul;83(2):261-6 [10901380.001]
  • [Cites] Int J Gynecol Cancer. 2007 Jan-Feb;17(1):68-75 [17291234.001]
  • (PMID = 20473913.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Bispecific; 0 / catumaxomab
  • [Other-IDs] NLM/ PMC2958458
  •  go-up   go-down


79. Kimura H, Iizasa T, Ishikawa A, Yoshino M, Shingyouji M, Kimura M, Hirata T, Odaka A, Matsubayasi K: Eradication of intractable malignant ascites by abdominocentesis, reinfusion of concentrated ascites, and adoptive immunotherapy with dendritic cells and activated killer cells in a patient with recurrent lung cancer: a case report. J Med Case Rep; 2008;2:372

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Eradication of intractable malignant ascites by abdominocentesis, reinfusion of concentrated ascites, and adoptive immunotherapy with dendritic cells and activated killer cells in a patient with recurrent lung cancer: a case report.
  • INTRODUCTION: Malignant ascites is often a sign of a terminal stage in several malignant diseases.
  • To control ascites, drainage and intra-abdominal chemotherapy are often used in those patients but eradication of ascites is difficult and prognosis is poor.
  • Abdominocentesis revealed peritoneal carcinomatosis resulting from abdominal recurrence from lung cancer.
  • To alleviate the dyspnea and abdominal distention, we drained the ascites aseptically and infused them intravenously back into the patient after removal of tumor cells by centrifugation, and then concentration by apheresis.
  • After the drainage of ascites, we intraperitoneally infused activated killer cells and dendritic cells from the patient's tumor-draining lymph nodes, together with 4.5 x 105U interleukin-2 in 50 ml saline by 2.1 ml/hour infuser balloon.Drastic decreases in the tumor cell count and in ascite retention were observed after several courses of ascites drainage, intravenous infusion and intraperitoneal immunotherapy.
  • The plasma protein level was maintained during the treatment notwithstanding the repeated drainage of ascites.
  • Cell surface marker analysis, cytotoxic activities against autologous tumor cells and interferon-gamma examination of ascites suggested the possibility that these effects were mediated by immunological responses of activated killer cells and dendritic cells infused intraperitoneally.
  • CONCLUSION: Combination of local administration of immune cells and infusion of concentrated cell free ascites may be applicable for patients afflicted with refractory ascites.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2001 Jul 1;92(1):71-6 [11443611.001]
  • [Cites] Cancer Invest. 2002;20(7-8):1118-22 [12449746.001]
  • [Cites] J Clin Oncol. 2003 Mar 1;21(5):799-806 [12610177.001]
  • [Cites] Anticancer Res. 1999 May-Jun;19(3B):2317-21 [10472351.001]
  • [Cites] Anticancer Res. 2005 Jan-Feb;25(1A):85-94 [15816523.001]
  • [Cites] Ann Surg. 2007 Apr;245(4):597-603 [17414609.001]
  • [Cites] Cancer Invest. 2005;23(2):155-72 [15813509.001]
  • (PMID = 19055844.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2613411
  •  go-up   go-down


80. Pourgholami MH, Yan Cai Z, Lu Y, Wang L, Morris DL: Albendazole: a potent inhibitor of vascular endothelial growth factor and malignant ascites formation in OVCAR-3 tumor-bearing nude mice. Clin Cancer Res; 2006 Mar 15;12(6):1928-35
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Albendazole: a potent inhibitor of vascular endothelial growth factor and malignant ascites formation in OVCAR-3 tumor-bearing nude mice.
  • PURPOSE: Angiogenesis and vessel hyperpermeability are the two factors leading to the formation of ascites.
  • Vascular endothelial growth factor (VEGF) plays a pivotal role in malignant ascites formation.
  • We have recently shown that albendazole inhibits peritoneal growth of human colorectal cancer cells (HT-29).
  • The present study was designed to find out if albendazole can suppress ascites formation in ascites-producing peritoneal carcinomatosis.
  • EXPERIMENTAL DESIGN: Female nude mice bearing peritoneal tumors of human ovarian cancer cells (OVCAR-3) were treated with albendazole.
  • Following i.p. inoculation and ascites development, mice were given i.p. albendazole (150 mg/kg) or the vehicle x 3 weekly for 4 weeks.
  • RESULTS: Whereas vehicle-treated mice developed overt ascites requiring repeated aspiration, ascites formation in the albendazole-treated mice was markedly suppressed.
  • Suppressed ascites production and reduced tumor vascularity observed was a result of dramatic reduction in tumor VEGF production as revealed by profoundly lower VEGF ascites fluid and plasma levels.
  • Examination of floating tumor cells collected from the peritoneal wash revealed profound down-regulation of VEGF mRNA in albendazole-treated mice.
  • CONCLUSIONS: These findings suggest for the first time that in nude mice bearing OVCAR-3 peritoneal tumors, by inhibiting VEGF production, albendazole abolishes tumor angiogenesis and ascites formation.
  • [MeSH-major] Albendazole / pharmacology. Ascites / prevention & control. Ovarian Neoplasms / drug therapy. Vascular Endothelial Growth Factor A / antagonists & inhibitors. Xenograft Model Antitumor Assays

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ALBENDAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16551879.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CA-125 Antigen; 0 / Protein Isoforms; 0 / RNA, Messenger; 0 / Vascular Endothelial Growth Factor A; F4216019LN / Albendazole
  •  go-up   go-down


81. Benedict SP, Ahuja M, Mammen KJ: Hormone refractory carcinoma prostate with peritoneal metastases and malignant ascites without skeletal involvement: A case report and review of literature. Indian J Urol; 2010 Apr;26(2):287-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hormone refractory carcinoma prostate with peritoneal metastases and malignant ascites without skeletal involvement: A case report and review of literature.
  • Peritoneal carcinomatosis is rare in prostate cancer especially in the absence of skeletal or other visceral metastases.
  • We report a case of hormone refractory adenocarcinoma prostate presenting with only peritoneal metastases and massive malignant ascites.
  • Palliation with docetaxel based cytotoxic chemotherapy resulted in clinical improvement of refractory ascites decreasing respiratory embarrassment and thereby improving the quality of life.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20877611.001).
  • [ISSN] 1998-3824
  • [Journal-full-title] Indian journal of urology : IJU : journal of the Urological Society of India
  • [ISO-abbreviation] Indian J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2938557
  • [Keywords] NOTNLM ; Metastasis / peritoneum / prostate cancer
  •  go-up   go-down


82. Bala L, Sharma A, Yellapa RK, Roy R, Choudhuri G, Khetrapal CL: (1)H NMR spectroscopy of ascitic fluid: discrimination between malignant and benign ascites and comparison of the results with conventional methods. NMR Biomed; 2008 Jul;21(6):606-14

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] (1)H NMR spectroscopy of ascitic fluid: discrimination between malignant and benign ascites and comparison of the results with conventional methods.
  • It is often difficult to distinguish benign ascites from malignant ascites by conventional examination of ascitic fluid.
  • Seventy ascitic fluid specimens (15 cytologically positive for malignant cells, eight cytologically negative for malignant cells but remaining suspicious for malignant ascites, and 47 due to liver cirrhosis) were subjected to (1)H NMR spectroscopy for quantitative estimation of 14 metabolites.
  • Patients with malignant ascites had significantly higher mean concentrations (microM) of beta-hydroxybutyrate (594 vs 61), lactate (5384 vs 2104), acetone (136 vs 69), and acetoacetate (122 vs 48) than patients with cirrhotic ascites, and significantly lower concentrations of glutamine (359 vs 615), citrate (62 vs 118), glucose (4933 vs 8411), tyrosine (44 vs 124), and phenylalanine (51 vs 93) (P < 0.05 for all).
  • The proposed model put five of the eight doubtful cases in the malignant group.
  • [MeSH-major] Ascites / diagnosis. Ascites / metabolism. Ascitic Fluid / chemistry. Magnetic Resonance Spectroscopy / methods. Protons
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Reproducibility of Results. Sensitivity and Specificity. Statistics as Topic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18205245.001).
  • [ISSN] 0952-3480
  • [Journal-full-title] NMR in biomedicine
  • [ISO-abbreviation] NMR Biomed
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Protons
  •  go-up   go-down


83. Burleson KM, Boente MP, Pambuccian SE, Skubitz AP: Disaggregation and invasion of ovarian carcinoma ascites spheroids. J Transl Med; 2006 Jan 24;4:6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disaggregation and invasion of ovarian carcinoma ascites spheroids.
  • BACKGROUND: Malignant ascites often develops in advanced stages of ovarian carcinoma, consisting of single and aggregated tumor cells, or spheroids.
  • However, little is known about the adhesive or invasive capabilities of spheroids, and whether this particular cellular component of the ascites can contribute to dissemination of ovarian cancer.
  • Here, we examined the invasive ability of ascites spheroids recovered from seven ovarian carcinoma patients and one primary peritoneal carcinoma (PPC) patient.
  • METHODS: Ascites spheroids were isolated from patients, purified, and immunohistochemical analyses were performed by a pathologist to confirm diagnosis.
  • RESULTS: Spheroids from all of the patients' ascites samples disaggregated on extracellular matrix components, with the PPC spheroids capable of complete disaggregation on type I collagen.
  • Additionally, all of the ascites spheroid samples adhered to and disaggregated on live human mesothelial cell monolayers, typically without invading them.
  • However, the PPC ascites spheroids and one ovarian carcinoma ascites spheroid sample occasionally formed invasive foci in the mesothelial cell monolayers, suggestive of a more invasive phenotype.
  • CONCLUSION: We present here in vitro assays using ascites spheroids that imitate the spread of ovarian cancer in vivo.
  • Our results suggest that systematic studies of the ascites cellular content are necessary to understand the biology of ovarian carcinoma.

  • COS Scholar Universe. author profiles.
  • Coriell Cell Repositories. culture/stock collections - Coriell Cell Repositories .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Exp Cell Biol. 1987;55(4):194-208 [3678576.001]
  • [Cites] Gynecol Oncol. 1988 Sep;31(1):103-12 [3410341.001]
  • [Cites] Eur J Cell Biol. 1988 Feb;45(2):224-9 [3366122.001]
  • [Cites] APMIS. 1988 May;96(5):433-44 [3288248.001]
  • [Cites] J Clin Invest. 1990 Sep;86(3):851-5 [2394835.001]
  • [Cites] Cancer Res. 1990 Oct 1;50(19):6130-8 [1698118.001]
  • [Cites] Gynecol Oncol. 2004 Apr;93(1):170-81 [15047232.001]
  • [Cites] Cancer Res. 1965 May;25:490-7 [14297487.001]
  • [Cites] Br J Cancer. 1964 Dec;18:730-42 [14264939.001]
  • [Cites] J Natl Cancer Inst. 1977 Jun;58(6):1849-53 [140943.001]
  • [Cites] Acta Cytol. 2002 Jul-Aug;46(4):697-703 [12146034.001]
  • [Cites] Anal Cell Pathol. 2001;23(3-4):107-28 [12082292.001]
  • [Cites] Am J Pathol. 2001 Dec;159(6):2071-80 [11733357.001]
  • [Cites] Am J Clin Pathol. 2001 Apr;115(4):517-24 [11293899.001]
  • [Cites] Exp Cell Res. 2001 Jan 15;262(2):180-96 [11139342.001]
  • [Cites] Int J Oncol. 1999 Mar;14(3):515-21 [10024685.001]
  • [Cites] Ann Oncol. 1998 Apr;9(4):437-42 [9636836.001]
  • [Cites] Cancer. 1997 Oct 15;80(8):1457-63 [9338470.001]
  • [Cites] Cancer Treat Rev. 1997 Mar;23(2):113-31 [9225962.001]
  • [Cites] J Cell Biochem. 1993 Mar;51(3):283-9 [8501130.001]
  • [Cites] N Engl J Med. 1993 Nov 18;329(21):1550-9 [8155119.001]
  • [Cites] Am J Obstet Gynecol. 1994 May;170(5 Pt 1):1285-96 [8178854.001]
  • [Cites] Cancer Res. 1994 Jan 1;54(1):276-80 [8261452.001]
  • [Cites] Exp Cell Res. 1985 Oct;160(2):499-513 [3899694.001]
  • [Cites] Am J Obstet Gynecol. 1974 Aug 1;119(7):991-4 [4276313.001]
  • [Cites] Cancer Res. 1973 Dec;33(12):3181-8 [4760534.001]
  • [Cites] Cancer Res. 1972 Aug;32(8):1663-6 [5044130.001]
  • [Cites] Exp Cell Res. 1972 Mar;71(1):75-80 [5063574.001]
  • [Cites] J Natl Cancer Inst. 1971 Jan;46(1):113-20 [5101993.001]
  • [Cites] J Biol Chem. 1982 May 25;257(10):5831-8 [6175633.001]
  • [Cites] Cancer Metastasis Rev. 1984;3(1):25-42 [6370418.001]
  • [Cites] Cancer Res. 1984 Jul;44(7):3090-7 [6373002.001]
  • [Cites] Cancer Metastasis Rev. 1983;2(1):5-23 [6616442.001]
  • [Cites] Science. 1983 Feb 25;219(4587):983-5 [6823562.001]
  • [Cites] Cancer Res. 1982 Nov;42(11):4574-83 [7127297.001]
  • [Cites] Biophys Struct Mech. 1982;9(2):83-8 [7150702.001]
  • [Cites] J Natl Cancer Inst. 1994 Jul 6;86(13):975-82 [8007019.001]
  • (PMID = 16433903.001).
  • [ISSN] 1479-5876
  • [Journal-full-title] Journal of translational medicine
  • [ISO-abbreviation] J Transl Med
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA106878-01A1; United States / NCI NIH HHS / CA / R01 CA106878-01A1
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1397876
  •  go-up   go-down


84. Burges A, Wimberger P, Kümper C, Gorbounova V, Sommer H, Schmalfeldt B, Pfisterer J, Lichinitser M, Makhson A, Moiseyenko V, Lahr A, Schulze E, Jäger M, Ströhlein MA, Heiss MM, Gottwald T, Lindhofer H, Kimmig R: Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study. Clin Cancer Res; 2007 Jul 1;13(13):3899-905
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study.
  • PURPOSE: Malignant ascites in ovarian carcinoma patients is associated with poor prognosis and reduced quality of life.
  • This multicenter phase I/II dose-escalating study investigated tolerability and efficacy of i.p. catumaxomab application in ovarian cancer patients with malignant ascites containing epithelial cell adhesion molecule (EpCAM)--positive tumor cells.
  • EXPERIMENTAL DESIGN: Twenty-three women with recurrent ascites due to pretreated refractory ovarian cancer were treated with four to five i.p. infusions of catumaxomab in doses of 5 to 200 microg within 9 to 13 days.
  • Treatment with catumaxomab resulted in significant and sustained reduction of ascites flow rate.
  • Tumor cell monitoring revealed a reduction of EpCAM-positive malignant cells in ascites by up to 5 log.
  • CONCLUSION: I.p. immunotherapy with catumaxomab prevented the accumulation of ascites and efficiently eliminated tumor cells with an acceptable safety profile.
  • This suggests that catumaxomab is a promising treatment option in ovarian cancer patients with malignant ascites.
  • [MeSH-major] Antibodies / therapeutic use. Antigens, CD3 / immunology. Antigens, Neoplasm / immunology. Ascites / therapy. Cell Adhesion Molecules / immunology. Immunotherapy / methods. Ovarian Neoplasms / complications. Ovarian Neoplasms / therapy

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17606723.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Antigens, CD3; 0 / Antigens, Neoplasm; 0 / Cell Adhesion Molecules; 0 / EPCAM protein, human; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


85. Oh SY, Kwon HC, Lee S, Lee DM, Yoo HS, Kim SH, Jang JS, Kim MC, Jeong JS, Kim HJ: A Phase II study of oxaliplatin with low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) for gastric cancer patients with malignant ascites. Jpn J Clin Oncol; 2007 Dec;37(12):930-5
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Phase II study of oxaliplatin with low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) for gastric cancer patients with malignant ascites.
  • BACKGROUND: Clinical studies regarding chemotherapy for gastric cancer patients with malignant ascites have been classically rather limited in scope, largely because peritoneal seeding produces no measurable lesions, and patients generally exhibited poor performance status.
  • METHODS: Gastric cancer patients with cytologically confirmed malignant ascites were treated with cycles of oxaliplatin at 85 mg/m(2) plus leucovorin 20 mg/m(2) on the first day of treatment, followed by 5-fluorouracil (5-FU) via a 400 mg/m(2) bolus and a 22 h continuous infusion of 600 mg/m(2) 5-FU on Days 1-2 at 2-week intervals.
  • Decreases or disappearances of ascites levels were observed in 17 (35.4%) patients.
  • CONCLUSION: The m-FOLFOX-4 regimen utilized herein was determined to be both safe and feasible even for gastric cancer patients with malignant ascites in poor performance status.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Ascites / etiology. Carcinoma / drug therapy. Palliative Care / methods. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Palliative Care.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18211984.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


86. Braunschweig T, Krieg RC, Bar-Or R, Smeets D, Schwamborn K, Fogt F, Nagel H, Hemmerlein B, Wellmann A: Protein profiling of non-malignant and malignant ascites by SELDI-TOF MS: proof of principle. Int J Mol Med; 2009 Jan;23(1):3-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Protein profiling of non-malignant and malignant ascites by SELDI-TOF MS: proof of principle.
  • Ascites is a common clinical symptom in liver cirrhosis, inflammatory disorders of the abdomen and a major late manifestation of metastatic malignancies.
  • In this work we examined differential analysis of the unbound proteins in the supernatant of ascites fluid by Protein-Chip SELDI mass spectrometry.
  • This study suggests that SELDI-TOF mass spectrometry appears to have great potential as a surrogate diagnostic tool to evaluate effusion specimens.
  • [MeSH-major] Ascites / diagnosis. Biomarkers, Tumor / analysis. Protein Array Analysis / methods. Proteins / analysis. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19082501.001).
  • [ISSN] 1107-3756
  • [Journal-full-title] International journal of molecular medicine
  • [ISO-abbreviation] Int. J. Mol. Med.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proteins
  •  go-up   go-down


87. Ströhlein MA: [Pleural effusions and ascites--surgical and palliative aspects]. Zentralbl Chir; 2010 Dec;135(6):508-15
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pleural effusions and ascites--surgical and palliative aspects].
  • [Transliterated title] Pleuraerguss und Aszites--chirurgische und palliative Aspekte.
  • BACKGROUND: Pleural effusions and ascites are associated with distressing symptoms like dyspnoea, intestinal obstruction, vomiting, nausea and pain.
  • In patients with ascites, paracentesis is able to control acute symptoms.
  • In patients with malignancy, pleural effusions and ascites may also be controlled by complete cytoreductive surgery and hyperthermic chemoperfusion.
  • In malignant ascites, intraperitoneal immunotherapy by catumaxomab is a novel and highly effective option, which controls ascites by targeted destruction of peritoneal cancer cells.
  • CONCLUSION: Various options for treatment of pleural effusions and ascites are available.
  • [MeSH-major] Ascites / surgery. Neoplasms / surgery. Palliative Care / methods. Pleural Effusion, Malignant / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © Georg Thieme Verlag KG Stuttgart ˙ New York.
  • (PMID = 21154207.001).
  • [ISSN] 1438-9592
  • [Journal-full-title] Zentralblatt für Chirurgie
  • [ISO-abbreviation] Zentralbl Chir
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Bispecific; 0 / Antineoplastic Agents; 0 / catumaxomab
  •  go-up   go-down


88. Spurgeon JM, Cotlar AM: Cytoreductive surgery in the management of malignant ascites from adenocarcinoma of unknown primary (ACUP). Curr Surg; 2005 Sep-Oct;62(5):500-3
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytoreductive surgery in the management of malignant ascites from adenocarcinoma of unknown primary (ACUP).
  • A case report is presented of a 62-year-old man with adenocarcinoma of unknown primary (ACUP) who was admitted with massive ascites from intraperitoneal carcinomatosis secondary to a gastrointestinal tract malignancy.
  • Cytoreductive surgery should be offered to some patients with peritoneal carcinomatosis because it may provide significant palliation.
  • [MeSH-major] Adenocarcinoma / therapy. Chemotherapy, Cancer, Regional Perfusion / methods. Neoplasm Invasiveness / pathology. Neoplasms, Unknown Primary / pathology. Palliative Care. Peritoneal Neoplasms / therapy
  • [MeSH-minor] Ascites / pathology. Chemotherapy, Adjuvant. Combined Modality Therapy. Disease Progression. Fatal Outcome. Humans. Immunohistochemistry. Laparotomy / methods. Male. Middle Aged. Omentum / pathology. Omentum / surgery. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16125606.001).
  • [ISSN] 0149-7944
  • [Journal-full-title] Current surgery
  • [ISO-abbreviation] Curr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


89. Kuemmerle A, Decosterd LA, Buclin T, Liénard D, Stupp R, Chassot PG, Mosimann F, Lejeune F: A phase I pharmacokinetic study of hypoxic abdominal stop-flow perfusion with gemcitabine in patients with advanced pancreatic cancer and refractory malignant ascites. Cancer Chemother Pharmacol; 2009 Jan;63(2):331-41
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I pharmacokinetic study of hypoxic abdominal stop-flow perfusion with gemcitabine in patients with advanced pancreatic cancer and refractory malignant ascites.
  • PURPOSE: As no curative treatment for advanced pancreatic and biliary cancer with malignant ascites exists, new modalities possibly improving the response to available chemotherapies must be explored.
  • [MeSH-major] Anoxia. Antimetabolites, Antineoplastic / pharmacokinetics. Ascites / drug therapy. Deoxycytidine / analogs & derivatives. Drug Delivery Systems / methods. Pancreatic Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18587581.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


90. Pappas J, Wolfson AD, Jung WJ, Oleszak EL, Helm CW, Freedman RS, Tsygankov AY, Platsoucas CD: Differential expression of CD3zeta message and protein in tumor infiltrating lymphocytes from solid tumor specimens and malignant ascites from patients with ovarian carcinoma. Anticancer Res; 2009 Nov;29(11):4673-82
Hazardous Substances Data Bank. L-TYROSINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of CD3zeta message and protein in tumor infiltrating lymphocytes from solid tumor specimens and malignant ascites from patients with ovarian carcinoma.
  • The expression of the CD3zeta subunit was investigated in fresh (uncultured) tumor-infiltrating lymphocytes (TILs) isolated from either solid tumor (ST) specimens or ascites (ASC) from patients with epithelial ovarian carcinoma (EOC).
  • [MeSH-minor] Aged. Aged, 80 and over. Ascites / metabolism. Ascites / pathology. Down-Regulation. Female. Humans. Immunoprecipitation. Middle Aged. Phosphorylation. Tyrosine / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20032419.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, CD3; 0 / CD3 antigen, zeta chain; 42HK56048U / Tyrosine
  •  go-up   go-down


91. Koide A, Maruyama M, Hasegawa K, Miyawaki Y, Tamura N, Ohbu M, Maruyama S, Takashima I, Ebuchi M: [An effective weekly paclitaxel administration for gastric cancer with malignant ascites--a case report]. Gan To Kagaku Ryoho; 2005 Oct;32(11):1752-4
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [An effective weekly paclitaxel administration for gastric cancer with malignant ascites--a case report].
  • CT of abdomen showed that malignant ascites had obviously accumulated, and she was admitted.
  • In CT of the abdomen that was taken in November in 2002, malignant ascites had obviously been decreasing and disappeared completely after that.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents, Phytogenic / administration & dosage. Ascites / drug therapy. Paclitaxel / administration & dosage. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16315930.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


92. Pan J: [Combined group A streptococcus preparation (sapylin) and cisplatin for malignant peritoneal effusion]. Zhonghua Zhong Liu Za Zhi; 2005 Jul;27(7):442-4
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Combined group A streptococcus preparation (sapylin) and cisplatin for malignant peritoneal effusion].
  • OBJECTIVE: To evaluate the effect of Group A streptococcus preparation (sapylin) combined with cisplatin on the malignant peritoneal effusion in patients with advanced cancer.
  • METHODS: Sixty advanced cancer patients with large amount of peritoneal effusion were divided into two groups: sapylin + cisplatin (DDP) group (30 patients) and control group (DDP alone, 30 cases).
  • CONCLUSION: Combined Group A streptococcus preparation (sapylin) and cisplatin is more effective than cisplatin alone for the malignant peritoneal effusion in patients with advanced cancer, and the adverse effects are tolerable.
  • [MeSH-major] Ascitic Fluid / pathology. Bacterial Proteins / administration & dosage. Biological Products / administration & dosage. Cisplatin / administration & dosage. Peritoneal Neoplasms / therapy. Streptococcus pyogenes / chemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16188135.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Antineoplastic Agents; 0 / Bacterial Proteins; 0 / Biological Products; 0 / Immunologic Factors; 0 / streptococcal preparation 722; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


93. Lee HK, Chae HS, Kim JS, Kim HK, Cho YS, Rho SY, Kang JH, Cho SG, Jang HS, Han K: Vascular endothelial growth factor levels in ascites between chemonaive and chemotreated patients. Yonsei Med J; 2008 Jun 30;49(3):429-35

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascular endothelial growth factor levels in ascites between chemonaive and chemotreated patients.
  • PURPOSE: Vascular endothelial growth factor (VEGF) levels in malignant ascites have high diagnostic value for their discrimination from ascites of non-malignant origin.
  • However, there have been no reports on the comparison of VEGF levels between malignant ascites of chemonaive and chemotreated patients.
  • MATERIALS AND METHODS: VEGF levels were measured in 44 ascites patients (cirrhosis ascites, 10; chemonaive patients, 21; chemotreated patients, 13) and compared to the level of carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA 19-9).
  • RESULTS: VEGF levels in malignant ascites of chemonaive and chemotreated patients were significantly higher than those in cirrhotic ascites (p<0.05).
  • VEGF levels in ascites of chemonaive patients were significantly higher than those in chemotreated patients (p<0.05).
  • Positive correlations were observed between VEGF and CEA (r=0.353, p<0.05) as well as between VEGF and CA19-9 (r=0.367, p<0.05) in ascites.
  • CONCLUSION: VEGF levels could be a useful tumor marker for malignant ascites, but its value should carefully be interpreted because of lesser reliability in chemotreated ones.
  • [MeSH-major] Ascites / drug therapy. Ascites / metabolism. Vascular Endothelial Growth Factor A / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Biol Markers. 2000 Oct-Dec;15(4):308-11 [11192826.001]
  • [Cites] World J Gastroenterol. 2006 Jun 28;12(24):3891-4 [16804977.001]
  • [Cites] Arch Intern Med. 2001 Dec 10-24;161(22):2733-7 [11732940.001]
  • [Cites] Cancer Res. 2002 Oct 1;62(19):5597-602 [12359773.001]
  • [Cites] World J Gastroenterol. 2003 Nov;9(11):2596-600 [14606105.001]
  • [Cites] Oncol Rep. 2004 Jan;11(1):73-80 [14654905.001]
  • [Cites] Ai Zheng. 2004 Jan;23(1):85-9 [14720382.001]
  • [Cites] Nature. 1968 Jul 13;219(5150):186-9 [5659650.001]
  • [Cites] Ann Intern Med. 1972 Oct;77(4):507-13 [4642731.001]
  • [Cites] Ann Intern Med. 1978 May;88(5):635-8 [646247.001]
  • [Cites] Cancer. 1981 Jan 1;47(1):207-14 [7459811.001]
  • [Cites] Clin Chem. 1983 Mar;29(3):549-52 [6825270.001]
  • [Cites] Cancer. 1986 Nov 1;58(9):2089-95 [3756825.001]
  • [Cites] Cancer. 1986 Dec 1;58(11):2489-93 [3021317.001]
  • [Cites] J Gastroenterol Hepatol. 1992 Mar-Apr;7(2):161-4 [1571498.001]
  • [Cites] J Gastroenterol Hepatol. 1994 Jul-Aug;9(4):396-400 [7948823.001]
  • [Cites] Am J Clin Oncol. 1997 Jun;20(3):247-50 [9167746.001]
  • [Cites] Cancer. 1999 Jan 1;85(1):178-87 [9921991.001]
  • [Cites] Eur J Cancer. 1998 Dec;34(13):2041-5 [10070308.001]
  • [Cites] Wiad Lek. 1998;51(11-12):484-91 [10222840.001]
  • [Cites] Ann Surg Oncol. 1999 Jun;6(4):373-8 [10379858.001]
  • [Cites] APMIS. 2004 Sep;112(9):585-7 [15601306.001]
  • [Cites] Tumour Biol. 2004 Sep-Dec;25(5-6):276-81 [15627892.001]
  • [Cites] J Natl Med Assoc. 2005 Feb;97(2):276-80 [15712792.001]
  • [Cites] J Natl Med Assoc. 2005 Jan;97(1):79-84 [15719876.001]
  • [Cites] Mol Cancer Ther. 2005 May;4(5):715-25 [15897235.001]
  • [Cites] Med Sci Monit. 2005 Mar;11(3):CR136-42 [15735567.001]
  • [Cites] South Med J. 2006 Mar;99(3):306-8 [16553110.001]
  • [Cites] Am J Obstet Gynecol. 2001 Feb;184(3):354-5 [11228486.001]
  • (PMID = 18581593.001).
  • [ISSN] 0513-5796
  • [Journal-full-title] Yonsei medical journal
  • [ISO-abbreviation] Yonsei Med. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen; 0 / Carcinoembryonic Antigen; 0 / Vascular Endothelial Growth Factor A
  • [Other-IDs] NLM/ PMC2615342
  •  go-up   go-down


94. Sugihara S, Ikuta Y, Kobayashi H, Tsuruta Y, Yonemitsu K, Toyama E, Teshima K: [Effective TS-1+paclitaxel administration for gastric cancer with malignant ascites--a case report]. Gan To Kagaku Ryoho; 2005 Dec;32(13):2109-11
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effective TS-1+paclitaxel administration for gastric cancer with malignant ascites--a case report].
  • We report a case in which TS-1 + paclitaxel (PTX) administration was effective for gastric cancer with malignant ascites.
  • He complained of abdominal fullness and ascites 18 months later.
  • Computed tomography (CT) showed complete loss of malignant ascites.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ascites / complications. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16352938.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


95. Buffon A, Casali EA, Cardoso VV, Zerbini LF, Robson SC, Sarkis JJ, Wink MR: Differential expression of nucleotide pyrophosphatase/phosphodiesterases by Walker 256 mammary cancer cells in solid tumors and malignant ascites. Life Sci; 2010 Mar 13;86(11-12):435-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of nucleotide pyrophosphatase/phosphodiesterases by Walker 256 mammary cancer cells in solid tumors and malignant ascites.
  • [MeSH-minor] Animals. Ascites / enzymology. Cations / metabolism. Kinetics. Neoplasm Proteins / metabolism. Neoplasm Transplantation. Nucleosides / metabolism. Nucleotides / metabolism. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Rats. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20117116.001).
  • [ISSN] 1879-0631
  • [Journal-full-title] Life sciences
  • [ISO-abbreviation] Life Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cations; 0 / Neoplasm Proteins; 0 / Nucleosides; 0 / Nucleotides; 0 / RNA, Messenger; EC 3.1.4.- / Phosphoric Diester Hydrolases; EC 3.6.1.- / Pyrophosphatases
  •  go-up   go-down


96. Zervos EE, Osborne D, Boe BA, Luzardo G, Goldin SB, Rosemurgy AS: Prognostic significance of new onset ascites in patients with pancreatic cancer. World J Surg Oncol; 2006;4:16
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of new onset ascites in patients with pancreatic cancer.
  • BACKGROUND: The purpose of this study was to determine risk factors for development of malignant ascites and its prognostic significance in patients with pancreatic cancer.
  • METHODS: A prospective database was queried to identify patients with pancreatic cancer who develop ascites.
  • Stage at presentation, size, and location of primary tumor, treatment received and length of survival after onset of ascites were determined.
  • Of which 4 patients (1 stage II, 3 stage III) underwent pancreaticoduodenectomy and manifested with ascites 2, 3, 24 and 47 months after surgery (tumor size 2.9 +/- 1.32 cm).
  • All but one of the remaining 11 patients (tumor size 4.4 +/- 3.38 cm) presented with metastatic disease, and all developed malignant ascites 9 months after diagnosis, dying 2 months later.
  • Resected patients lived longer before the onset of ascites, but not after.
  • CONCLUSION: Once diagnosed, ascites in pancreatic cancer patients heralds imminent death.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 [12568441.001]
  • [Cites] Lancet. 2001 Nov 10;358(9293):1576-85 [11716884.001]
  • [Cites] Ann Chir. 2000 Sep;125(7):625-30 [11051691.001]
  • [Cites] Bull Cancer. 2004 May;91(5):E113-32 [15568226.001]
  • [Cites] Cancer Control. 2004 Jan-Feb;11(1):23-31 [14749620.001]
  • [Cites] J Am Coll Surg. 2004 Jun;198(6):999-1011 [15194082.001]
  • [Cites] Arch Surg. 1998 Apr;133(4):361-5 [9565114.001]
  • [Cites] Surg Oncol Clin N Am. 1998 Jan;7(1):135-42 [9443991.001]
  • [Cites] Br J Surg. 1996 Jan;83(1):6-14 [8653366.001]
  • [Cites] Br J Surg. 1995 Aug;82(8):1127-9 [7648172.001]
  • [Cites] Radiology. 1973 Jun;107(3):577-83 [4702536.001]
  • [Cites] Ann Intern Med. 1992 Aug 1;117(3):215-20 [1616215.001]
  • [Cites] Mayo Clin Proc. 1986 Jun;61(6):467-71 [3012216.001]
  • [Cites] Hepatogastroenterology. 2004 Nov-Dec;51(60):1827-31 [15532836.001]
  • [Cites] Hepatology. 1988 Sep-Oct;8(5):1104-9 [3417231.001]
  • (PMID = 16569225.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1513572
  •  go-up   go-down


97. Won JY, Choi SY, Ko HK, Kim SH, Lee KH, Lee JT, Lee DY: Percutaneous peritoneovenous shunt for treatment of refractory ascites. J Vasc Interv Radiol; 2008 Dec;19(12):1717-22

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Percutaneous peritoneovenous shunt for treatment of refractory ascites.
  • PURPOSE: To evaluate the usefulness of a percutaneously placed peritoneovenous shunt (PVS) in patients with refractory ascites.
  • MATERIALS AND METHODS: Under fluoroscopic and ultrasonographic (US) guidance, the authors placed a PVS in 55 patients (39 men and 16 women; mean age, 56 years) with refractory ascites and symptomatic abdominal distention.
  • The cause of ascites was liver cirrhosis (n = 36), carcinomatosis (n = 17), ruptured cysts with polycystic kidney disease (n = 1), and idiopathic refractory ascites (n = 1).
  • Complications occurred in 17 of the 55 patients (31%): five patients had variceal bleeding; three patients had ascites leakage; two patients each had disseminated intravascular coagulopathy, transient abdominal pain, shunt infection, and venous thrombosis; and one patient had pulmonary thromboembolism.
  • There was no significant difference in shunt patency between the two groups with benign and malignant ascites.
  • CONCLUSIONS: The percutaneous placement of a PVS was a technically feasible and effective method for symptomatic relief of refractory ascites.
  • [MeSH-major] Ascites / surgery. Peritoneovenous Shunt

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18948021.001).
  • [ISSN] 1535-7732
  • [Journal-full-title] Journal of vascular and interventional radiology : JVIR
  • [ISO-abbreviation] J Vasc Interv Radiol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Tuzun Y, Yilmaz S, Dursun M, Canoruc F, Celik Y, Cil T, Boyraz T: How to increase the diagnostic value of malignancy-related ascites: discriminative ability of the ascitic tumour markers. J Int Med Res; 2009 Jan-Feb;37(1):87-95
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] How to increase the diagnostic value of malignancy-related ascites: discriminative ability of the ascitic tumour markers.
  • Making a differential diagnosis between malignant and non-malignant ascites is an important clinical issue, but cytological examination has a relatively low diagnostic sensitivity.
  • This study aimed to find a discriminative model that distinguished between malignancy-related and non-malignant ascites.
  • The study included 107 patients: 50 with non-malignant and 57 with malignant ascites.
  • Ascites was analysed using a range of tumour markers and standard cytology.
  • Standardized canonical discriminant function coefficients were used to distinguish between ascites types.
  • The combination of carbohydrate antigen (CA) 15-3, carcinoembryonic antigen (CEA) and cytokeratin 19 fragments (CYFRA-21.1) discriminated between malignancy-related ascites and non-malignant ascites with an accuracy of 98.8% compared with an accuracy of 77.8% for cytological examination.
  • In conclusion, the use of a discriminant function constructed from a combination of CA15-3, CEA and CYFRA-21.1 could distinguish malignant from non-malignant ascites with greater accuracy than cytological examination.
  • [MeSH-major] Ascites / complications. Ascites / metabolism. Biomarkers, Tumor / analysis. Neoplasms / complications. Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19215677.001).
  • [ISSN] 0300-0605
  • [Journal-full-title] The Journal of international medical research
  • [ISO-abbreviation] J. Int. Med. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


99. Khan FY: Ascites in the state of Qatar: aetiology and diagnostic value of ascitic fluid analysis. Singapore Med J; 2007 May;48(5):434-9
Hazardous Substances Data Bank. GLUCOSE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ascites in the state of Qatar: aetiology and diagnostic value of ascitic fluid analysis.
  • INTRODUCTION: Ascites is common and represents an important feature of liver disease and other diseases.
  • The aim of this study is to determine the causes of ascites in Qatar, and to evaluate the value of ascitic fluid analysis in different types of ascites.
  • METHODS: This is a descriptive, prospective study of all patients admitted to the medical department at Hamad General Hospital with ascites between January 2004 and January 2005.
  • Liver cirrhosis was the most frequent cause of ascites in 62 patients (59.6 percent), while chronic alcoholism was the main cause of liver cirrhosis.
  • Other frequent causes of ascites were malignant ascites in 12 patients (11.5 percent), malignancy-related ascites in ten patients (9.6 percent), and tuberculous peritonitis in eight patients (7.7 percent).
  • Based on the serum-ascites albumin gradient (SAAG), different causes of ascites were divided into two main groups.
  • The most common cause of high gradient ascites was liver cirrhosis, while the most common causes of low gradient ascites were carcinomatous peritonitis and tuberculous peritonitis.
  • The mean ascitic lactate dehydrogenase (LDH) level was higher in cancer patients than in tuberculous patients (p-value is less than 0.05), while the mean ascitic glucose concentration was significantly lower in peritoneal tuberculosis than in carcinomatous peritonitis (p-value is less than 0.05).
  • CONCLUSION: Liver cirrhosis is the main cause of ascites in Qatar.
  • SAAG is a better distinguishing marker for separating ascites related to portal hypertension from other causes of ascites without portal hypertension.
  • In patients with low gradient ascites, ascitic fluid glucose and LDH level are useful indicators for separating tuberculous from malignant ascites.
  • [MeSH-major] Ascites / etiology. Ascitic Fluid / chemistry
  • [MeSH-minor] Adult. Aged. Albumins / analysis. Female. Glucose / analysis. Humans. L-Lactate Dehydrogenase / analysis. Liver Cirrhosis / complications. Liver Cirrhosis / diagnosis. Male. Middle Aged. Neoplasms / complications. Neoplasms / diagnosis. Peritoneal Neoplasms / complications. Peritoneal Neoplasms / diagnosis. Serum Albumin / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17453102.001).
  • [ISSN] 0037-5675
  • [Journal-full-title] Singapore medical journal
  • [ISO-abbreviation] Singapore Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Singapore
  • [Chemical-registry-number] 0 / Albumins; 0 / Serum Albumin; EC 1.1.1.27 / L-Lactate Dehydrogenase; IY9XDZ35W2 / Glucose
  •  go-up   go-down


100. Easson AM, Bezjak A, Ross S, Wright JG: The ability of existing questionnaires to measure symptom change after paracentesis for symptomatic ascites. Ann Surg Oncol; 2007 Aug;14(8):2348-57
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The ability of existing questionnaires to measure symptom change after paracentesis for symptomatic ascites.
  • BACKGROUND: Symptomatic malignant ascites is a problem for patients with advanced intra-abdominal malignancy.
  • METHODS: Patients with symptomatic ascites completed four questionnaires before and 24 hours after paracentesis.
  • These tests were Edmonton Symptom Assessment System-Ascites Modification (ESAS:AM), Memorial Symptom Assessment Scale-Short Form, European Organization for the Research and Treatment of Cancer (EORTC) Core Quality of Life Questionnaire (QLQ-C30), and the EORTC Core Quality of Life Questionnaire, 26-item pancreatic cancer module (QLQ-PAN26).
  • Patients reported major symptoms at baseline; symptom scores were highest for the clinically recognized symptoms of ascites.
  • For future clinical trials of symptomatic ascites, the QLQ-C30 and the ESAS:AM together, or the QLQ-C30 with the addition of the QLQ-PAN26 ascites and abdominal pain subscales could be used.
  • [MeSH-major] Ascites / therapy. Gastrointestinal Neoplasms / therapy. Ovarian Neoplasms / therapy. Paracentesis / methods. Quality of Life. Surveys and Questionnaires

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17505860.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down






Advertisement